##### Table of Contents



UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

---

(Mark One)

|  |  |                                                                                          
|- |  | -----------------------------------------------------------------------------------------
|x |  | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934. 
| 
|  |  | For the quarterly period ended June 28, 2002                                             
| 
|  |  | OR                                                                                       
| 
|o |  | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934.

---

|                                    |  |                                 
|----------------------------------- |  | --------------------------------
|FOR THE QUARTER ENDED
JUNE 28, 2002 |  | COMMISSION FILE NUMBER
001-31257

ADVANCED MEDICAL OPTICS, INC.

|                       |  |                                       
|---------------------- |  | --------------------------------------
|A DELAWARE CORPORATION |  | IRS EMPLOYER IDENTIFICATION
33-0986820

1700 E. ST. ANDREW PLACE, SANTA ANA, CALIFORNIA 92799-6162

TELEPHONE NUMBER 714/247-8200

FORMER ADDRESS:

2525 DUPONT DRIVE, IRVINE, CALIFORNIA 92612

TELEPHONE NUMBER 714/246-4500

Indicate by a check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

(1) x yes o no
(2) x yes o no

Indicate the number of shares outstanding of each of the issuers classes of
common stock as of the latest practicable date.

As of August 9, 2002 there were 28,723,512 shares of common stock outstanding.

1



---

TABLE OF CONTENTS



|                                                                                                                          |                                                             |                                                            |  |  |  |  |  | 
|------------------------------------------------------------------------------------------------------------------------- | ----------------------------------------------------------- | ---------------------------------------------------------- |  |  |  |  |  | 
|PART I  FINANCIAL INFORMATION                                                                                           
|                                                                                                                          |                                                             | Unaudited Condensed Combined Statements of Earnings       
|                                                                                                                          |                                                             | Unaudited Condensed Combined Balance Sheets               
|                                                                                                                          |                                                             | Unaudited Condensed Combined Statements of Cash Flows     
|                                                                                                                          |                                                             | Notes to Unaudited Condensed Combined Financial Statements
|MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE QUARTER ENDED JUNE 28, 2002
|QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK                                                               
|CERTAIN FACTORS AND TRENDS AFFECTING AMO AND ITS BUSINESSES                                                              
|PART II  OTHER INFORMATION                                                                                              
|                                                                                                                          | Item 4. Submission of Matters to a Vote of Security Holders
|                                                                                                                          | Item 5. Other Information                                  
|                                                                                                                          | Item 6. Exhibits and Reports on Form 8-K                   
|SIGNATURE                                                                                                                



---



##### Table of Contents



ADVANCED MEDICAL OPTICS, INC.
FORM 10-Q FOR THE QUARTER ENDED JUNE 28, 2002

INDEX

|                                                              |  |  |           |                                                                                       |  |                                                                                                                         |       |                                                                                 |      |      |       | 
|------------------------------------------------------------- |  |  | --------- | ------------------------------------------------------------------------------------- |  | ----------------------------------------------------------------------------------------------------------------------- | ----- | ------------------------------------------------------------------------------- | ---- | ---- | ----- | 
|                                                              |  |  |           |                                                                                       |  |                                                                                                                         |       |                                                                                 |      | Page
|                                                              |  |  |           |                                                                                       |  |                                                                                                                         |       |                                                                                 |      |     
|PART I
  FINANCIAL INFORMATION                               |  |  |           |                                                                                      
|                                                              |  |  | ITEM 1   | FINANCIAL STATEMENTS                                                                  |  |                                                                                                                         |      
|                                                              |  |  | (A        | )                                                                                     |  | Unaudited
Condensed Combined Statements of Earnings  Three Months and Six Months Ended June 28, 2002
and June 29, 2001 |       |                                                                                 | 3    |     
|                                                              |  |  | (B        | )                                                                                     |  | Unaudited
Condensed Combined Balance Sheets  June 28, 2002 and December 31, 2001                                       |       |                                                                                 | 4    |     
|                                                              |  |  | (C        | )                                                                                     |  | Unaudited Condensed Combined Statements of Cash
Flows  Six Months Ended June 28, 2002
and June 29, 2001                |       |                                                                                 | 5    |     
|                                                              |  |  | (D        | )                                                                                     |  | Notes to Unaudited Condensed Combined
Financial Statements                                                              |       |                                                                                 | 6-13 |     
|                                                              |  |  | ITEM 2   | MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS |  |                                                                                                                         | 14-25 |                                                                                
|                                                              |  |  | ITEM 3   | QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK                            |  |                                                                                                                         | 26-29 |                                                                                
|                                                              |  |  |           |                                                                                       |  |                                                                                                                         |       | CERTAIN FACTORS AND TRENDS AFFECTING ADVANCED
MEDICAL OPTICS AND ITS BUSINESSES |      |      | 30-51 | 
|PART II   OTHER INFORMATION                                  |  |  |           |                                                                                      
|ITEM 4   SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS |  |  | 52        |                                                                                      
|ITEM 5   OTHER INFORMATION                                   |  |  | 52        |                                                                                      
|ITEM 6   EXHIBITS AND REPORTS ON FORM 8-K                    |  |  | 52-53     |                                                                                      
|Signature                                                     |  |  | 54        |                                                                                      

2



---



##### Table of Contents






PART I  FINANCIAL INFORMATION




Advanced Medical Optics, Inc.
Unaudited Condensed Combined Statements of Earnings
(In thousands)

|                                                                        |                                                  |   |                    |        |                  |   |          |        |          |   |         |         |  |   |         |         |  
|----------------------------------------------------------------------- | ------------------------------------------------ | - | ------------------ | ------ | ---------------- | - | -------- | ------ | -------- | - | ------- | ------- |  | - | ------- | ------- | -
|                                                                        |                                                  |   | Three Months Ended |        | Six Months Ended
|                                                                        |                                                  |   |                    |        |                 
|                                                                        |                                                  |   | June 28,           |        | June 29,         |   | June 28, |        | June 29,
|                                                                        |                                                  |   | 2002               |        | 2001             |   | 2002     |        | 2001    
|                                                                        |                                                  |   |                    |        |                  |   |          |        |         
|Net sales                                                               |                                                  | $ | 137,678            |        |                  | $ | 139,208  |        |          | $ | 251,676 |         |  | $ | 260,019 |        
|Cost of sales                                                           |                                                  |   | 53,419             |        |                  |   | 53,948   |        |          |   | 97,696  |         |  |   | 104,283 |        
|                                                                        |                                                  |   |                    |        |                  |   |          |        |          |   |         |         |  |   |         |        
|                                                                        | Gross margin                                     |   |                    | 84,259 |                  |   |          | 85,260 |          |   |         | 153,980 |  |   |         | 155,736 |  
|                                                                        |                                                  |   |                    |        |                  |   |          |        |          |   |         |         |  |   |         |        
|Selling, general and
administrative                                     |                                                  |   | 59,615             |        |                  |   | 58,488   |        |          |   | 113,785 |         |  |   | 120,606 |        
|Research and development                                                |                                                  |   | 7,884              |        |                  |   | 7,173    |        |          |   | 14,868  |         |  |   | 14,437  |        
|                                                                        |                                                  |   |                    |        |                  |   |          |        |          |   |         |         |  |   |         |        
|Operating income                                                        |                                                  |   | 16,760             |        |                  |   | 19,599   |        |          |   | 25,327  |         |  |   | 20,693  |        
|                                                                        |                                                  |   |                    |        |                  |   |          |        |          |   |         |         |  |   |         |        
|Non-operating expense (income)                                          |                                                  |   |                    |        |                  |   |          |        |          |   |         |         |  |   |         |        
|                                                                        | Interest expense                                 |   |                    | 1,485  |                  |   |          | 854    |          |   |         | 2,166   |  |   |         | 1,678   |  
|                                                                        | Unrealized loss
(gain) on derivative
instruments |   |                    | 1,719  |                  |   |          | 363    |          |   |         | 1,931   |  |   |         | (958    | )
|                                                                        | Other, net                                       |   |                    | 2,976  |                  |   |          | 24     |          |   |         | 3,027   |  |   |         | (66     | )
|                                                                        |                                                  |   |                    |        |                  |   |          |        |          |   |         |         |  |   |         |        
|                                                                        |                                                  |   | 6,180              |        |                  |   | 1,241    |        |          |   | 7,124   |         |  |   | 654     |        
|                                                                        |                                                  |   |                    |        |                  |   |          |        |          |   |         |         |  |   |         |        
|Earnings before income
taxes                                            |                                                  |   | 10,580             |        |                  |   | 18,358   |        |          |   | 18,203  |         |  |   | 20,039  |        
|Provision for income
taxes                                              |                                                  |   | 4,020              |        |                  |   | 5,410    |        |          |   | 6,917   |         |  |   | 5,877   |        
|                                                                        |                                                  |   |                    |        |                  |   |          |        |          |   |         |         |  |   |         |        
|Earnings before
cumulative effect of
change in accounting
principle     |                                                  |   | 6,560              |        |                  |   | 12,948   |        |          |   | 11,286  |         |  |   | 14,162  |        
|Cumulative effect of
change in accounting
principle, net of $160
of tax |                                                  |   |                   |        |                  |   |         |        |          |   |        |         |  |   | (391    | )      
|                                                                        |                                                  |   |                    |        |                  |   |          |        |          |   |         |         |  |   |         |        
|Net earnings                                                            |                                                  | $ | 6,560              |        |                  | $ | 12,948   |        |          | $ | 11,286  |         |  | $ | 13,771  |        
|                                                                        |                                                  |   |                    |        |                  |   |          |        |          |   |         |         |  |   |         |        

See accompanying notes to unaudited condensed combined financial statements.

3



---



##### Table of Contents






Advanced Medical Optics, Inc.
Unaudited Condensed Combined Balance Sheets(In thousands)

|                                       |                                      |                              |         |          |         |              |         |         |         | 
|-------------------------------------- | ------------------------------------ | ---------------------------- | ------- | -------- | ------- | ------------ | ------- | ------- | ------- | 
|                                       |                                      |                              |         | June 28, |         | December 31,
|                                       |                                      |                              |         | 2002     |         | 2001        
|                                       |                                      |                              |         |          |         |             
|ASSETS                                
|Current assets                         |                                      |                              |         |          |         |              |         |        
|                                       | Cash and equivalents                 |                              | $       | 83,102   |         |              | $       | 6,957   |        
|                                       | Trade receivables, net               |                              |         | 108,026  |         |              |         | 114,724 |        
|                                       | Inventories                          |                              |         | 61,479   |         |              |         | 65,237  |        
|                                       | Other current assets                 |                              |         | 15,373   |         |              |         | 23,634  |        
|                                       |                                      |                              |         |          |         |              |         |        
|                                       |                                      | Total current assets         |         |          | 267,980 |              |         |         | 210,552 | 
|Property, plant and equipment, net     |                                      |                              | 35,729  |          |         |              | 28,293  |        
|Other assets                           |                                      |                              | 40,176  |          |         |              | 37,248  |        
|Goodwill                               |                                      |                              | 102,875 |          |         |              | 100,374 |        
|Intangibles, net                       |                                      |                              | 1,339   |          |         |              | 999     |        
|                                       |                                      |                              |         |          |         |              |         |        
|                                       |                                      | Total assets                 |         | $        | 448,099 |              |         | $       | 377,466 | 
|                                       |                                      |                              |         |          |         |              |         |        
|LIABILITIES AND EQUITY                
|Current liabilities                    |                                      |                              |         |          |         |              |         |        
|                                       | Current portion of long-term debt    |                              | $       | 500      |         |              | $       | 18,988  |        
|                                       | Accounts payable                     |                              |         | 22,836   |         |              |         | 29,583  |        
|                                       | Accrued compensation                 |                              |         | 9,264    |         |              |         | 16,652  |        
|                                       | Other accrued expenses               |                              |         | 29,015   |         |              |         | 20,328  |        
|                                       |                                      |                              |         |          |         |              |         |        
|                                       |                                      | Total current liabilities    |         |          | 61,615  |              |         |         | 85,551  | 
|Long-term debt, net of current portion |                                      |                              | 296,710 |          |         |              | 75,809  |        
|Other liabilities                      |                                      |                              | 9,852   |          |         |              | 2,176   |        
|Commitments and contingencies          |                                      |                              |         |          |         |              |         |        
|Equity                                 |                                      |                              |         |          |         |              |         |        
|                                       | Allergan, Inc. net investment        |                              |         | 80,381   |         |              |         | 215,653 |        
|                                       | Accumulated other comprehensive loss |                              |         | (459     | )       |              |         | (1,723  | )      
|                                       |                                      |                              |         |          |         |              |         |        
|                                       |                                      | Total equity                 |         |          | 79,922  |              |         |         | 213,930 | 
|                                       |                                      |                              |         |          |         |              |         |        
|                                       |                                      | Total liabilities and equity |         | $        | 448,099 |              |         | $       | 377,466 | 
|                                       |                                      |                              |         |          |         |              |         |        

See accompanying notes to unaudited condensed combined financial statements.

4



---



##### Table of Contents






Advanced Medical Optics, Inc.
Unaudited Condensed Combined Statements of Cash Flows
(In thousands)

|                                                    |                                                                   |                                                     |                                        |                                           |        |                  |         |          |         |        |        |  
|--------------------------------------------------- | ----------------------------------------------------------------- | --------------------------------------------------- | -------------------------------------- | ----------------------------------------- | ------ | ---------------- | ------- | -------- | ------- | ------ | ------ | -
|                                                    |                                                                   |                                                     |                                        |                                           |        | Six Months Ended
|                                                    |                                                                   |                                                     |                                        |                                           |        |                 
|                                                    |                                                                   |                                                     |                                        |                                           |        | June 28,         |         | June 29,
|                                                    |                                                                   |                                                     |                                        |                                           |        | 2002             |         | 2001    
|                                                    |                                                                   |                                                     |                                        |                                           |        |                  |         |         
|Cash flows provided by operating activities         |                                                                   |                                                     |                                        |                                           |        |                  |         |         
|Net earnings                                        |                                                                   | $                                                   | 11,286                                 |                                           |        | $                | 13,771  |         
|Non cash items included in net earnings:            |                                                                   |                                                     |                                        |                                           |        |                  |         |         
|                                                    | Cumulative effect of accounting
change for derivative instruments |                                                     |                                        |                                          |        |                  |         | 551      |        
|                                                    | Depreciation and amortization                                     |                                                     |                                        | 7,140                                     |        |                  |         | 11,047   |        
|                                                    | Deferred
income taxes                                             |                                                     |                                        | 5,720                                     |        |                  |         |         |        
|                                                    | Loss on investments and assets                                    |                                                     |                                        | 1,635                                     |        |                  |         | 225      |        
|                                                    | Unrealized loss/(gain) on derivatives                             |                                                     |                                        | 1,931                                     |        |                  |         | (958     | )      
|                                                    | Changes in assets and liabilities:                                |                                                     |                                        |                                           |        |                  |         |          |        
|                                                    |                                                                   |                                                     | Trade receivables                      |                                           |        | 13,540           |         |          |         | 4,732  |       
|                                                    |                                                                   |                                                     | Inventories                            |                                           |        | 3,521            |         |          |         | (2,141 | )     
|                                                    |                                                                   |                                                     | Other current assets                   |                                           |        | 4,105            |         |          |         | 2,555  |       
|                                                    |                                                                   |                                                     | Accounts payable                       |                                           |        | (7,599           | )       |          |         | (3,913 | )     
|                                                    |                                                                   |                                                     | Accrued expenses and other liabilities |                                           |        | 7,730            |         |          |         | (5,149 | )     
|                                                    |                                                                   |                                                     | Other non-current assets               |                                           |        | (8,887           | )       |          |         | (4,213 | )     
|                                                    |                                                                   |                                                     |                                        |                                           |        |                  |         |         
|                                                    |                                                                   |                                                     |                                        | Net cash provided by operating
activities |        |                  | 40,122  |          |         |        | 16,507 |  
|                                                    |                                                                   |                                                     |                                        |                                           |        |                  |         |         
|Cash flows from investing activities                |                                                                   |                                                     |                                        |                                           |        |                  |         |         
|Additions to property, plant and equipment          |                                                                   |                                                     | (8,720                                 | )                                         |        |                  | (1,638  | )       
|Additions to capitalized internal-use software      |                                                                   |                                                     | (875                                   | )                                         |        |                  | (1,198  | )       
|Additions to demonstration and bundled equipment    |                                                                   |                                                     | (2,664                                 | )                                         |        |                  | (2,326  | )       
|                                                    |                                                                   |                                                     |                                        |                                           |        |                  |         |         
|                                                    |                                                                   |                                                     |                                        | Net cash used in investing activities     |        |                  | (12,259 | )        |         |        | (5,162 | )
|                                                    |                                                                   |                                                     |                                        |                                           |        |                  |         |         
|Proceeds from issuance of senior subordinated notes |                                                                   |                                                     | 197,194                                |                                           |        |                  |        |         
|Long-term debt borrowings                           |                                                                   |                                                     | 108,363                                |                                           |        |                  |        |         
|Repayment of long-term debt                         |                                                                   |                                                     | (111,363                               | )                                         |        |                  |        |         
|Distributions to Allergan, Inc., net of advances    |                                                                   |                                                     | (146,558                               | )                                         |        |                  | (18,748 | )       
|                                                    |                                                                   |                                                     |                                        |                                           |        |                  |         |         
|                                                    |                                                                   | Net cash provided by (used in) financing
activities |                                        |                                           | 47,636 |                  |         |          | (18,748 | )     
|Effect of exchange rates on cash and equivalents    |                                                                   |                                                     | 646                                    |                                           |        |                  | (432    | )       
|                                                    |                                                                   |                                                     |                                        |                                           |        |                  |         |         
|Net increase (decrease) in cash and equivalents     |                                                                   |                                                     | 76,145                                 |                                           |        |                  | (7,835  | )       
|Cash and equivalents at beginning of period         |                                                                   |                                                     | 6,957                                  |                                           |        |                  | 12,641  |         
|                                                    |                                                                   |                                                     |                                        |                                           |        |                  |         |         
|Cash and equivalents at end of period               |                                                                   | $                                                   | 83,102                                 |                                           |        | $                | 4,806   |         
|                                                    |                                                                   |                                                     |                                        |                                           |        |                  |         |         
|Supplemental disclosure of cash flow information    |                                                                   |                                                     |                                        |                                           |        |                  |         |         
|Cash paid for:                                      |                                                                   |                                                     |                                        |                                           |        |                  |         |         
|                                                    | Interest                                                          |                                                     | $                                      | 2,719                                     |        |                  | $       | 1,776    |        
|                                                    | Income taxes                                                      |                                                     | $                                      | 1,113                                     |        |                  | $       | 63       |        

See accompanying notes to unaudited condensed combined financial statements.

5



---



##### Table of Contents






Advanced Medical Optics, Inc.
Notes to Unaudited Condensed Combined Financial Statements

Note 1: Description of Business

On January 22, 2002, Allergan, Inc. (Allergan) announced a plan to spin off its
optical medical device business consisting of ophthalmic surgical and contact
lens care product business lines to Allergan stockholders. The 28,723,512
shares of the new optical medical device company, Advanced Medical Optics, Inc.
(AMO or the Company), were distributed on June 29, 2002 to Allergan
stockholders of record on June 14, 2002 by means of a tax-free dividend. The
distribution resulted in AMO operating as an independent entity with publicly
traded common stock.

On June 29, 2002 in accordance with the contribution and distribution
agreement, cash and equity were reduced by approximately $50.1 million due to a
cash distribution to Allergan.

Note 2: Basis of Presentation

In the opinion of management, the accompanying unaudited condensed combined
financial statements contain all adjustments necessary (consisting only of
normal recurring accruals) to present fairly the financial information
contained therein. These statements do not include all disclosures required by
accounting principles generally accepted in the United States of
America for annual financial statements and
should be read in conjunction with the audited combined financial statements of
the Company for the year ended December 31, 2001. The results of operations
for the three and six months ended June 28, 2002 are not necessarily indicative
of the results to be expected for the year ending December 31, 2002.

Allergan did not account for the business that comprises AMO on the basis of
separate legal entities, subsidiaries, divisions or segments. The accompanying
unaudited combined financial statements as of December 31, 2001 and for each of
the periods ended June 28, 2002 and June 29, 2001 include those assets,
liabilities, revenues and expenses directly attributable to AMOs operations
and allocations of certain Allergan corporate assets, liabilities and expenses
to AMO. These amounts have been allocated to AMO on the basis that is
considered by Allergan management to reflect most fairly or reasonably the utilization
of the services provided to or the benefit obtained by the Company.
Allergan
believes the methods used to allocate these amounts are reasonable and
consistent with prior periods. The accompanying unaudited combined balance
sheet as of June 28, 2002 includes those assets and liabilities directly
related to the optical medical device business. All material intercompany
balances have been eliminated. At June 28, 2002, approximately $7.0 million of
intercompany payables were converted to third party payables to Allergan. The
financial information included herein does not necessarily reflect what the
financial position and results of operations of the Company would have been had
it operated as a stand-alone public entity during the periods covered, and may
not be indicative of future operations or financial position. Subsequent to
the distribution, the Company estimates that it will incur incremental annual
pre-tax costs of approximately $58 million associated with being an independent
public company. Such incremental annual costs include approximately
$7 million for cost of sales, $31 million for selling,

6



---



##### Table of Contents



Advanced Medical Optics, Inc.
Notes to Unaudited Condensed Combined Financial Statements (continued)

general and administrative expenses including accounting, information systems,
legal, human resources and other costs, $1 million for research and development
costs, and interest expense of $19 million, including the estimated annual
amortization of capitalized debt origination fees. The estimate of incremental
interest expense is based on the incurrence of $300
million of debt at a weighted average interest rate of 6.89%, including the
benefit of interest rate swaps.

Note 3: Recently Adopted Accounting Standards

In July 2001, Statement of Financial Accounting Standards No. 141, Business
Combinations (SFAS No. 141), was issued. SFAS No. 141 required that the
purchase method of accounting be used for all business combinations initiated
after June 30, 2001 as well as all purchase method combinations completed after
June 30, 2001. SFAS No. 141 also required the Company to evaluate its existing
intangible assets and goodwill that were acquired in prior business
combinations, and to make any necessary reclassifications in order to conform
with the new criteria in SFAS No. 141 for recognition of intangibles apart from
goodwill.

Additionally, in July 2001, Statement of Financial Accounting Standards No.
142, Goodwill and Other Intangible Assets (SFAS No. 142), was issued and is
effective for all periods of fiscal years beginning after December 15, 2001
(January 1, 2002 for the Company). SFAS No. 142 establishes accounting and
reporting standards for intangible assets. SFAS No. 142 requires goodwill and
intangible assets with indefinite useful lives be evaluated annually for
impairment rather than amortized. Upon adoption of SFAS No. 142, the Company is
also required to test goodwill and intangible assets with indefinite useful
lives for impairment within the first interim period with any impairment loss
being recognized as a cumulative effect of a change in accounting principle.

In connection with the transitional goodwill impairment evaluation, SFAS No.
142 requires the Company to perform an assessment of whether there is an
indication that goodwill and intangible assets with indefinite useful lives are
impaired as of the date of adoption. To accomplish this, the Company must
identify its reporting units and determine the carrying value of each reporting
unit by assigning the assets and liabilities, including the existing goodwill
and intangible assets, to those reporting units as of the date of adoption. The
Company then has up to six months from the date of adoption to determine the
fair value of each reporting unit and compare it to the reporting units
carrying amount. To the extent a reporting units carrying amount exceeds its
fair value, an indication exists that the reporting units goodwill may be
impaired.

The Company adopted the provisions of SFAS No. 141 on June 30, 2001 and SFAS
No. 142 on January 1, 2002, effective with Allergans adoption of the new
accounting standard. Allergans adoption did not result in a negative impact on
Allergans Consolidated Financial Statements. The Company is required to
complete a separate assessment of goodwill and intangibles on a

7



---



##### Table of Contents



Advanced Medical Optics, Inc.
Notes to Unaudited Condensed Combined Financial Statements (continued)

stand-alone basis. The Companys separate assessment is not expected to result
in a negative impact on its combined financial statements.

The components of amortizable intangibles and goodwill were as follows:

Intangibles

|                             |            |        |               |              |                   |        |        |              |             |   |       |       |  |   |        |        |  
|---------------------------- | ---------- | ------ | ------------- | ------------ | ----------------- | ------ | ------ | ------------ | ----------- | - | ----- | ----- |  | - | ------ | ------ | -
|                             |            |        | June 28, 2002 |              | December 31, 2001
|                             |            |        |               |              |                  
|                             |            |        | Gross         |              | Accumulated       |        | Gross  |              | Accumulated
|(In thousands)               |            | Amount |               | Amortization |                   | Amount |        | Amortization
|                             |            |        |               |              |                   |        |        |              |            
|Amortized Intangible Assets: |            |        |               |              |                   |        |        |              |             |   |       |       |  |   |        |       
|                             | Licensing  |        | $             | 4,426        |                   |        | $      | (3,148       | )           |   | $     | 3,940 |  |   | $      | (3,004 | )
|                             | Trademarks |        |               | 86           |                   |        |        | (25          | )           |   |       | 78    |  |   |        | (15    | )
|                             |            |        |               |              |                   |        |        |              |             |   |       |       |  |   |        |       
|                             |            | $      | 4,512         |              |                   | $      | (3,173 | )            |             | $ | 4,018 |       |  | $ | (3,019 | )     
|                             |            |        |               |              |                   |        |        |              |             |   |       |       |  |   |        |       

Amortization expense for the three and six months ended June 28, 2002
and June 29, 2001 was approximately $78,000 and $154,000, respectively.

Estimated amortization expense for years ending December 31, 2002, 2003, 2004,
2005, 2006 and thereafter are $352,000, $401,000, $401,000, $185,000,
$96,000 and $58,000, respectively.

Goodwill

|               |                          |               |         |                   |  |   |         |        | 
|-------------- | ------------------------ | ------------- | ------- | ----------------- |  | - | ------- | ------ | 
|(In thousands) |                          | June 28, 2002 |         | December 31, 2001
|               |                          |               |         |                   | 
|Goodwill:      |                          |               |         |                   |  |   |         |       
|               | United States            |               | $       | 12,783            |  |   | $       | 12,783 | 
|               | Asia Pacific             |               |         | 25,306            |  |   |         | 22,805 | 
|               | Manufacturing Operations |               |         | 64,786            |  |   |         | 64,786 | 
|               |                          |               |         |                   |  |   |         |       
|               |                          | $             | 102,875 |                   |  | $ | 100,374 |       
|               |                          |               |         |                   |  |   |         |       

There was no activity related to goodwill during the six months ended June 28,
2002, except for the impact of foreign currency fluctuations.

Pro forma financial information related to the adoption of SFAS No. 142 is as
follows:

|                                  |  |                        |       |                          |  |               |        |               |  |   |        |  |  |   |        | 
|--------------------------------- |  | ---------------------- | ----- | ------------------------ |  | ------------- | ------ | ------------- |  | - | ------ |  |  | - | ------ | 
|                                  |  | For the quarters ended |       | For the six months ended
|                                  |  |                        |       |                         
|(In thousands)                    |  | June 28, 2002          |       | June 29, 2001            |  | June 28, 2002 |        | June 29, 2001
|                                  |  |                        |       |                          |  |               |        |              
|Net earnings                      |  | $                      | 6,560 |                          |  | $             | 12,948 |               |  | $ | 11,286 |  |  | $ | 13,771 | 
|Add back:                         |  |                        |       |                          |  |               |        |               |  |   |        |  |  |   |        | 
|Goodwill amortization,
net of tax |  |                        |      |                          |  |               | 1,343  |               |  |   |       |  |  |   | 2,701  | 
|                                  |  |                        |       |                          |  |               |        |               |  |   |        |  |  |   |        | 
|Adjusted net earnings             |  | $                      | 6,560 |                          |  | $             | 14,291 |               |  | $ | 11,286 |  |  | $ | 16,472 | 
|                                  |  |                        |       |                          |  |               |        |               |  |   |        |  |  |   |        | 

In October 2001, Statement of Financial Accounting Standards No. 144,
Accounting for the Impairment or Disposal of Long-Lived Assets (SFAS No.
144), was issued. SFAS No. 144 superseded Statement No. 121, Accounting for
the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed
Of, and the accounting and reporting provisions of APB Opinion No. 30,
Reporting the Results of Operations  Reporting the effects of Disposal of a
Segment of a Business, and Extraordinary, Unusual and

8



---



##### Table of Contents



Advanced Medical Optics, Inc.
Notes to Unaudited Condensed Combined Financial Statements (continued)

Infrequently Occurring Events and Transactions, for the disposal of a segment
of a business. SFAS No. 144 retained the requirement in Opinion No. 30 to
report separately discontinued operations and extended that reporting to a
component of an entity that either has been disposed of or is classified as
held for sale. The Company adopted the provisions of SFAS No. 144 for the
quarter ended March 29, 2002. The adoption of SFAS No. 144 did not have a
material impact on the Companys combined financial statements.

In April 2002, Statement of Financial Accounting Standards No. 145, Rescission
of FASB Statements No. 4, 44, and 64, Amendment of FASB Statement No. 13, and
Technical Corrections (SFAS No. 145) was issued. SFAS No. 145 rescinds SFAS
No. 4, which required all gains and losses from extinguishment of debt to be
aggregated and, if material, classified as an extraordinary item, net of
related income tax effect. Upon adoption of SFAS No. 145, we will be required
to apply the criteria in APB Opinion No. 30, Reporting the Results of
Operations  Reporting the Effects of Disposal of a Segment of a Business, and
Extraordinary, Unusual and Infrequently Occurring Events and Transactions
(Opinion No. 30), in determining the classification of gains and losses
resulting from the extinguishment of debt. SFAS No. 145 is effective for
annual periods beginning after May 15, 2002, with earlier adoption encouraged.
The Company elected to early-adopt SFAS No. 145 during the quarter ended June
28, 2002. The adoption of SFAS 145 did not have a material effect on the
Companys combined financial statements.

Note 4: Inventories

Components of inventories were:

|                                                                                                                      |       |   |                |        |              |   |        |        | 
|--------------------------------------------------------------------------------------------------------------------- | ----- | - | -------------- | ------ | ------------ | - | ------ | ------ | 
|                                                                                                                      |       |   | June 28,       |        | December 31,
|                                                                                                                      |       |   | 2002           |        | 2001        
|                                                                                                                      |       |   |                |        |             
|                                                                                                                      |       |   | (in thousands)
|Finished goods, including
inventory on consignment
with customers of $6,882
and $6,653 in 2002 and 2001,
respectively |       | $ | 44,652         |        |              | $ | 51,479 |       
|Work in process                                                                                                       |       |   | 5,560          |        |              |   | 5,078  |       
|Raw materials                                                                                                         |       |   | 11,267         |        |              |   | 8,680  |       
|                                                                                                                      |       |   |                |        |              |   |        |       
|                                                                                                                      | Total |   | $              | 61,479 |              |   | $      | 65,237 | 
|                                                                                                                      |       |   |                |        |              |   |        |       

Note 5: Debt and Interest Rate Swap Agreements

At June 28, 2002, the Company had $197.2 million, net of $2.8 million of
original issue discount, of 9-1/4% senior subordinated notes due July 15, 2010
outstanding. Interest on the senior subordinated notes is payable on
January 15 and July 15 of each year, commencing
January 15, 2003. The notes are
redeemable at the option of the Company, in whole or in part, at any
time on or after July 15, 2006 at various redemption
prices.

In addition, the Company entered into a senior credit facility,
consisting of a $100.0 million term loan and a $35.0 million revolving line of credit. Currently, approximately
$17.0 million of the revolving line of credit has been reserved to support
letters of credit issued on the Companys behalf.

A portion of the proceeds from the senior
subordinated notes and the term loan were used to repay debt in
Japan. As a result of the prepayment of the Japan debt and the
adoption of SFAS No. 145, $3.5 million of early debt
extinguishment costs were incurred and are recorded in Other,
net on the accompanying condensed combined statement of
earnings.

9



---



##### Table of Contents



Advanced Medical Optics, Inc.
Notes to Unaudited Condensed Combined Financial Statements (continued)

The senior credit facility provides that the Company will maintain certain
financial and operating covenants which include, among other provisions,
maintaining specific leverage and interest coverage ratios. Certain covenants
under the senior credit facility and the indenture relating to the senior
subordinated notes also limit the incurrence of additional indebtedness and
restrict dividend payments.

The aggregate maturities of total long-term debt are as follows: $1.0 million
each year between 2003 and 2006; $48.0 million in 2007 and $248.0 million after
2007.

In June and July 2002, the Company entered into various interest rate swap agreements which
effectively convert the interest rate on $150.0 million of the senior
subordinated notes from a fixed to a floating rate and convert the interest
rate on $50.0 million of the $100.0 million term loan from a floating rate to a
fixed rate. The interest rate swaps have maturity dates beginning in
2005 and
qualify as either fair value or cash flow hedges. Changes in fair value of
these swap agreements are recorded in other comprehensive income to the extent
such changes are effective and as long as the fair value or cash flow hedge
requirements are met.

At June 28, 2002, the fair value of $(2.0) million of the interest rate swap
agreements related to the senior subordinated notes is recorded in Other liabilities.

Note 6: Income Taxes

The Companys operations were historically included in Allergans consolidated
U.S. federal and state income tax returns and in the tax returns of certain
Allergan foreign subsidiaries. The provision for income taxes has been
determined as if the Company had filed separate tax returns
under its existing structure for the periods presented. Accordingly, the
effective tax rate of the Company in future years could vary from its
historical effective tax rate depending on the Companys future legal structure
and tax elections. A majority of income taxes were paid by Allergan and
reflected through the Allergan, Inc. net investment account.

Note 7: Commitments and Contingencies

In conjunction with the spin-off from Allergan, the Company has entered into
various facility leases worldwide. Future minimum rental payments under
non-cancelable operating lease commitments with a term of more than one year
are as follows: $6.8 million in 2003; $4.5 million in 2004; $3.8 million in
2005; $3.9 million in 2006; $2.4 million in 2007 and $18.4 million thereafter.

The Company is involved in various litigation and claims arising in the normal
course of business. Management believes that recovery or liability with respect
to any pending lawsuits or asserted claims, will not have a material adverse
effect on the Companys combined financial position or results of operations.

10



---



##### Table of Contents



Advanced Medical Optics, Inc.
Notes to Unaudited Condensed Combined Financial Statements (continued)

Note 8: Other Comprehensive Income

The following table summarizes components of comprehensive income (in
thousands):

|                                         |  |                    |        |               |  |            |     |            |  |            |        |            |  |   |        |     |  |  |   |  |  |   |        |  
|---------------------------------------- |  | ------------------ | ------ | ------------- |  | ---------- | --- | ---------- |  | ---------- | ------ | ---------- |  | - | ------ | --- |  |  | - |  |  | - | ------ | -
|                                         |  | Three Months Ended
|                                         |  |                   
|                                         |  | June 28, 2002      |        | June 29, 2001
|                                         |  |                    |        |              
|                                         |  |                    |        |               |  | Tax        |     |            |  |            |        |            |  |   |        | Tax |  |  |   | 
|                                         |  | Before-tax         |        | (expense)     |  | Net-of-tax |     | Before-tax |  | (expense)  |        | Net-of-tax
|                                         |  | amount             |        | or benefit    |  | amount     |     | amount     |  | or benefit |        | amount    
|                                         |  |                    |        |               |  |            |     |            |  |            |        |           
|Unrealized loss on
derivatives           |  | $                  | (2,028 | )             |  |            | 771 |            |  | $          | (1,257 | )          |  | $ |       |     |  |  |  |  |  | $ |       |  
|Foreign currency
translation
adjustments |  | $                  | 3,028  |               |  | $          |    |            |  |            | 3,028  |            |  | $ | (1,264 | )   |  |  |  |  |  |   | (1,264 | )
|                                         |  |                    |        |               |  |            |     |            |  |            |        |            |  |   |        |     |  |  |   |  |  |   |        |  
|Net earnings                             |  |                    |        |               |  |            |     |            |  |            | 6,560  |            |  |   |        |     |  |  |   |  |  |   | 12,948 |  
|                                         |  |                    |        |               |  |            |     |            |  |            |        |            |  |   |        |     |  |  |   |  |  |   |        |  
|Total comprehensive
income               |  |                    |        |               |  |            |     |            |  | $          | 8,331  |            |  |   |        |     |  |  |   |  |  | $ | 11,684 |  
|                                         |  |                    |        |               |  |            |     |            |  |            |        |            |  |   |        |     |  |  |   |  |  |   |        |  

|                                         |  |                  |        |               |  |            |     |            |  |            |        |            |  |   |    |     |  |  |   |  |  |   |        | 
|---------------------------------------- |  | ---------------- | ------ | ------------- |  | ---------- | --- | ---------- |  | ---------- | ------ | ---------- |  | - | -- | --- |  |  | - |  |  | - | ------ | 
|                                         |  | Six Months Ended
|                                         |  |                 
|                                         |  | June 28, 2002    |        | June 29, 2001
|                                         |  |                  |        |              
|                                         |  |                  |        |               |  | Tax        |     |            |  |            |        |            |  |   |    | Tax |  |  |   | 
|                                         |  | Before-tax       |        | (expense)     |  | Net-of-tax |     | Before-tax |  | (expense)  |        | Net-of-tax
|                                         |  | amount           |        | or benefit    |  | amount     |     | amount     |  | or benefit |        | amount    
|                                         |  |                  |        |               |  |            |     |            |  |            |        |           
|Unrealized loss on
derivatives           |  | $                | (2,028 | )             |  |            | 771 |            |  | $          | (1,257 | )          |  | $ |   |     |  |  |  |  |  | $ |       | 
|Foreign currency
translation
adjustments |  | $                | 2,521  |               |  |            |    |            |  |            | 2,521  |            |  | $ | 73 |     |  |  |  |  |  |   | 73     | 
|                                         |  |                  |        |               |  |            |     |            |  |            |        |            |  |   |    |     |  |  |   |  |  |   |        | 
|Net earnings                             |  |                  |        |               |  |            |     |            |  |            | 11,286 |            |  |   |    |     |  |  |   |  |  |   | 13,771 | 
|                                         |  |                  |        |               |  |            |     |            |  |            |        |            |  |   |    |     |  |  |   |  |  |   |        | 
|Total comprehensive
income               |  |                  |        |               |  |            |     |            |  | $          | 12,550 |            |  |   |    |     |  |  |   |  |  | $ | 13,844 | 
|                                         |  |                  |        |               |  |            |     |            |  |            |        |            |  |   |    |     |  |  |   |  |  |   |        | 

11



---



##### Table of Contents



Advanced Medical Optics, Inc.
Notes to Unaudited Condensed Combined Financial Statements (continued)

Note 9: Business Segment Information

As a part of Allergan, the Company operated in regions or geographic operating
segments. The United States information is presented separately as it is the
Companys headquarters country, and U.S. sales represented 29.0% and 30.6% of
total net sales in the quarters ended June 28, 2002 and June 29, 2001,
respectively, and 29.7% and 31.6% of total net sales for the six months ended
June 28, 2002 and June 29, 2001, respectively. Additionally, sales in Japan
represented 25.8% and 25.0% of total net sales in the quarters ended June 28,
2002 and June 29, 2001, respectively, and 25.6% and 22.8% of total net sales
for the six months ended June 28, 2002 and June 29, 2001, respectively. No
other country, or single customer, generates over 10% of total net sales.
Operations for the Europe Region
also include sales to customers in Africa and the Middle East, and operations
in the Asia Pacific Region include sales to customers in Australia and New
Zealand.

Operating income attributable to each operating segment is based upon the
management assignment of costs to such regions, which includes the
manufacturing standard cost of goods produced by the Companys manufacturing
operations (or the cost to acquire goods from third parties), freight, duty and
local distribution costs, and royalties. Operating income for all operating
segments and manufacturing operations also includes a charge for corporate
services and asset utilization which permits management to better measure
segment performance by including a cost of capital in the determination of
operating income for each segment.

Income from manufacturing operations is not assigned to geographic regions
because most manufacturing operations produce products for more than one
region. Research and development costs are corporate costs.

Identifiable assets for each geographic operating segment consist of trade
receivables, inventories and property, plant and equipment. All other assets
are assigned to general corporate as corporate maintains responsibility for
all other assets. Corporate assets are primarily cash and equivalents,
goodwill, intangibles and other assets. Assets in each geographic operating
segment have not changed materially since December 31, 2001.

12



---



##### Table of Contents



Advanced Medical Optics, Inc.
Notes to Unaudited Condensed Combined Financial Statements (continued)

Geographic Operating Segments

|                                    |  |           |         |                        |  |          |         |          |  |   |        |   |  |   |        |  
|----------------------------------- |  | --------- | ------- | ---------------------- |  | -------- | ------- | -------- |  | - | ------ | - |  | - | ------ | -
|                                    |  | Net Sales |         | Operating Income(Loss)
|                                    |  |           |         |                       
|                                    |  | 2nd Qtr.  |         | 2nd Qtr.               |  | 2nd Qtr. |         | 2nd Qtr.
|(In thousands)                      |  | 2002      |         | 2001                   |  | 2002     |         | 2001    
|                                    |  |           |         |                        |  |          |         |         
|United States                       |  | $         | 39,924  |                        |  | $        | 42,650  |          |  | $ | 8,764  |   |  | $ | 7,499  |  
|Europe                              |  |           | 44,560  |                        |  |          | 40,791  |          |  |   | 12,108 |   |  |   | 10,648 |  
|Asia Pacific                        |  |           | 45,826  |                        |  |          | 47,667  |          |  |   | 12,403 |   |  |   | 13,926 |  
|Other                               |  |           | 7,368   |                        |  |          | 8,100   |          |  |   | 512    |   |  |   | 462    |  
|                                    |  |           |         |                        |  |          |         |          |  |   |        |   |  |   |        |  
|Segments total                      |  |           | 137,678 |                        |  |          | 139,208 |          |  |   | 33,787 |   |  |   | 32,535 |  
|Manufacturing operations            |  |           |        |                        |  |          |        |          |  |   | 831    |   |  |   | 512    |  
|Research and development            |  |           |        |                        |  |          |        |          |  |   | (7,884 | ) |  |   | (7,173 | )
|Elimination of inter-company profit |  |           |        |                        |  |          |        |          |  |   | (6,166 | ) |  |   | (9,078 | )
|General corporate                   |  |           |        |                        |  |          |        |          |  |   | (3,808 | ) |  |   | 2,803  |  
|                                    |  |           |         |                        |  |          |         |          |  |   |        |   |  |   |        |  
|Total                               |  | $         | 137,678 |                        |  | $        | 139,208 |          |  | $ | 16,760 |   |  | $ | 19,599 |  
|                                    |  |           |         |                        |  |          |         |          |  |   |        |   |  |   |        |  

|                                    |  |                  |         |                        |  |          |         |          |  |   |         |   |  |   |         |  
|----------------------------------- |  | ---------------- | ------- | ---------------------- |  | -------- | ------- | -------- |  | - | ------- | - |  | - | ------- | -
|                                    |  | Net Sales        |         | Operating Income(Loss)
|                                    |  |                  |         |                       
|                                    |  | Six Months Ended |         | Six Months Ended      
|                                    |  |                  |         |                       
|                                    |  | June 28,         |         | June 29,               |  | June 28, |         | June 29,
|(In thousands)                      |  | 2002             |         | 2001                   |  | 2002     |         | 2001    
|                                    |  |                  |         |                        |  |          |         |         
|United States                       |  | $                | 74,785  |                        |  | $        | 82,272  |          |  | $ | 14,035  |   |  | $ | 12,186  |  
|Europe                              |  |                  | 79,251  |                        |  |          | 78,265  |          |  |   | 17,551  |   |  |   | 14,779  |  
|Asia Pacific                        |  |                  | 84,324  |                        |  |          | 83,790  |          |  |   | 20,558  |   |  |   | 19,268  |  
|Other                               |  |                  | 13,316  |                        |  |          | 15,692  |          |  |   | 557     |   |  |   | (470    | )
|                                    |  |                  |         |                        |  |          |         |          |  |   |         |   |  |   |         |  
|Segments total                      |  |                  | 251,676 |                        |  |          | 260,019 |          |  |   | 52,701  |   |  |   | 45,763  |  
|Manufacturing operations            |  |                  |        |                        |  |          |        |          |  |   | 1,950   |   |  |   | 1,878   |  
|Research and development            |  |                  |        |                        |  |          |        |          |  |   | (14,868 | ) |  |   | (14,437 | )
|Elimination of inter-company profit |  |                  |        |                        |  |          |        |          |  |   | (10,680 | ) |  |   | (17,698 | )
|General corporate                   |  |                  |        |                        |  |          |        |          |  |   | (3,776  | ) |  |   | 5,187   |  
|                                    |  |                  |         |                        |  |          |         |          |  |   |         |   |  |   |         |  
|Total                               |  | $                | 251,676 |                        |  | $        | 260,019 |          |  | $ | 25,327  |   |  | $ | 20,693  |  
|                                    |  |                  |         |                        |  |          |         |          |  |   |         |   |  |   |         |  

In each geographic segment the Company markets products in two product lines:
Ophthalmic Surgical and Contact Lens Care. The Ophthalmic Surgical product
line markets intraocular lenses, phacoemulsification equipment, viscoelastics,
and other products related to cataract and refractive surgery. The Contact
Lens Care product line markets cleaning, storage and disinfection products for
the consumer contact lens market. The Company provides global marketing
strategy teams to ensure development and execution of a consistent marketing
strategy for products in all geographic operating segments. There are no
transfers between product lines.

Net Sales by Product Line

|                    |  |                    |         |                  |  |          |         |          |  |   |         |  |  |   |         | 
|------------------- |  | ------------------ | ------- | ---------------- |  | -------- | ------- | -------- |  | - | ------- |  |  | - | ------- | 
|                    |  | Three Months Ended |         | Six Months Ended
|                    |  |                    |         |                 
|                    |  | June 28,           |         | June 29,         |  | June 28, |         | June 29,
|(In thousands)      |  | 2002               |         | 2001             |  | 2002     |         | 2001    
|                    |  |                    |         |                  |  |          |         |         
|Ophthalmic Surgical |  | $                  | 70,901  |                  |  | $        | 65,526  |          |  | $ | 128,313 |  |  | $ | 122,218 | 
|Contact Lens Care   |  |                    | 66,777  |                  |  |          | 73,682  |          |  |   | 123,363 |  |  |   | 137,801 | 
|                    |  |                    |         |                  |  |          |         |          |  |   |         |  |  |   |         | 
|Total Net Sales     |  | $                  | 137,678 |                  |  | $        | 139,208 |          |  | $ | 251,676 |  |  | $ | 260,019 | 
|                    |  |                    |         |                  |  |          |         |          |  |   |         |  |  |   |         | 

13



---



##### Table of Contents



ADVANCED MEDICAL OPTICS




MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS FOR THE QUARTER ENDED JUNE 28, 2002

OVERVIEW

We are a global leader in the development, manufacture and marketing of medical
devices for the eye and contact lens care products. Our products in the
ophthalmic surgical market include intraocular lenses, phacoemulsification
systems, viscoelastics and surgical packs used in cataract surgery, and
microkeratomes used in refractive surgery. Our products in the contact lens
care market include disinfecting solutions to destroy harmful microorganisms in
and on the surface of contact lenses, daily cleaners to remove undesirable film
and deposits from contact lenses, enzymatic cleaners to remove protein deposits
from contact lenses and lens rewetting drops to provide added wearing comfort.

We have operations in approximately 20 countries and sell our products in
approximately 60 countries. As part of Allergan, we had organized our
operations into four regions: North America, Latin America, Asia Pacific and
Europe. Operations for the Europe Region included sales to customers in Africa
and the Middle East, and operations in the Asia Pacific Region included sales
to customers in Australia and New Zealand. Since the distribution, we have
organized our operations into three regions:



| |  |  | Americas (North and South America);                                                        
| | - |  | -------------------------------------------------------------------------------------------
|
| |  |  | Japan; and                                                                                 
|
| |  |  | Europe, Africa and Asia Pacific (excluding Japan, but including
Australia and New Zealand).

Separation from Allergan

Allergan spun-off its existing optical medical device business by contributing
all of the assets related to the two business lines that comprise the optical
medical device business to us and distributing all of our outstanding shares of
stock to its stockholders. We had no material assets, liabilities or activities
as a separate corporate entity until Allergans contribution to us of the
optical medical device business. The contribution of assets and distribution to
Allergan stockholders was completed on June 29, 2002. As a result of the
distribution, we are an independent public company and Allergan no longer
maintains any stock ownership in us.

On June 29, 2002 in accordance with the contribution and distribution
agreement, our cash and equity were reduced by approximately $50.1 million due
to a cash distribution to Allergan.

14



---



##### Table of Contents



Advanced Medical Optics, Inc.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS FOR THE QUARTER ENDED JUNE 28, 2002

OVERVIEW (Continued)

We anticipate incurring incremental annual pre-tax costs of approximately $58
million associated with being an independent public company. Our management
believes that these costs are a reasonable estimate of the incremental costs we
will incur as an independent company; however, we cannot assure you that actual
costs will not exceed this estimate in a material amount. These incremental
annual costs include approximately:



| |  |  | $7 million for cost of sales;                                                                                                                                                                                                                                                   
| | - |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|
| |  |  | $31 million for selling, general and administrative expenses
including accounting, legal, human resources and other costs;                                                                                                                                                      
|
| |  |  | $1 million for research and development costs; and                                                                                                                                                                                                                              
|
| |  |  | $19 million for interest expense, including the estimated annual
amortization of capitalized debt origination fees. This estimate is
based on the incurrence of $300 million of debt at a weighted average
interest rate of 6.89%, including the benefit of interest rate swaps.

Allergan did not account for our business on the basis of separate legal
entities, subsidiaries, divisions or segments. The accompanying unaudited
combined financial statements as of December 31, 2001 and for each of the
periods ended June 28, 2002 and June 29, 2001 include those assets,
liabilities, revenues and expenses directly attributable to our operations and
allocations of certain Allergan corporate assets, liabilities and expenses.
These amounts have been allocated on a basis that is considered by
Allergan management
to reflect most fairly or reasonably the utilization of the services provided
to us or the benefit obtained by us. Allergan believes the methods used to allocate
these amounts to us are reasonable and consistent with prior periods. The
accompanying unaudited combined balance sheet as of June 28, 2002 includes
those assets and liabilities directly related to the optical medical device
business. All material intercompany balances have been eliminated. The
financial information included herein does not necessarily reflect what the
financial position and results of our operations would have been had we
operated as a stand-alone public entity during the periods covered, and may not
be indicative of future operations or financial position.

As part of Allergan, we historically participated in various Allergan
administered functions including shared services surrounding selling, general
and administrative expenses, retirement and other post retirement benefit
plans, income taxes and cash management. Additionally, Allergan has
manufactured certain of our products. Shared services include finance, human
resources, information systems and legal services. Our allocated portion of the
expenses for these services are included in selling, general and administrative
expense in our unaudited combined statements of earnings. For the three months
ended June 28, 2002 and June 29, 2001, these

15



---



##### Table of Contents



Advanced Medical Optics, Inc.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS FOR THE QUARTER ENDED JUNE 28, 2002

OVERVIEW (Continued)

allocated expenses were $15.0 million and $8.4 million, respectively. For the
six months ended June 28, 2002 and June 29, 2001, these allocated expenses were
$23.2 million and $17.0 million, respectively.
The Allergan retirement plans and other post retirement benefit plans, which
primarily provide medical benefits, historically have covered all Allergan
employees. We have included in our unaudited combined statements of earnings
allocations for expenses attributable to our employees participating in these
plans. We have also included in our unaudited combined financial statements
assets and liabilities associated with certain foreign plans to the extent that
these plans were transferred to us.

Our income historically has been included in consolidated income tax returns
filed by Allergan and most of the related income taxes have been paid by
Allergan. Allergan has managed its tax position for the benefit of its entire
portfolio of businesses. Allergans tax methodologies and elections are not
necessarily reflective of the tax methodologies and elections that we would
have followed or will follow as a stand-alone company. Our income tax expense
has been recorded as if we filed tax returns separate from Allergan.

Cash and equivalents consist of cash in banks and repurchase agreements with
financial institutions with original maturities of 90 days or less. We
historically have participated in a centralized cash management program
administered by Allergan. Cash and equivalents include only those amounts that
will be considered part of our operations upon the distribution.

Prior to the distribution, we entered into several agreements with Allergan in
connection with, among other things, transitional services, employee matters,
manufacturing and tax sharing. Under the transitional services agreement,
Allergan provides us, on an interim basis, transitional services such as
facilities subleases, research and development services, retail channel support
and general and administrative services. In addition, the transitional services
agreement provides that we will provide certain limited transitional services
to Allergan on an interim basis. Such services include: facilities subleases,
retail channel support, and certain general and administrative services.

The transitional services agreement sets forth charges generally intended to
allow Allergan to fully recover the allocated costs of providing the services,
plus all out-of-pocket costs and expenses, except that we will pay to Allergan
a commission related to our products that are sold by them during the
transition period. We will recover costs from Allergan in a similar manner for
services provided by us. Access to research and development facilities will be
provided to us for up to three years following the distribution. With limited
exceptions, we do not expect that the other transitional services will extend
beyond the 12-month period

16



---



##### Table of Contents



Advanced Medical Optics, Inc.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS FOR THE QUARTER ENDED JUNE 28, 2002

OVERVIEW (Continued)

following the distribution. We cannot assure you that the costs we incur under
the transitional services agreement will be equal to or less than the costs of
providing these services internally.

Under the manufacturing agreement, Allergan manufactures certain contact lens
care products and VITRAX for a period of up to 3 years from the date of the
distribution. We purchase these products from Allergan at a price equal to
Allergans fully allocated costs plus 10%. If we are unable to either build or
obtain regulatory approval for new facilities or locate and obtain regulatory
approval for third party manufacturers to produce our products, our business
may be harmed.

The tax sharing agreement governs Allergans and our respective rights,
responsibilities and obligations with respect to taxes for any tax period
ending before, on or after the distribution. Generally, Allergan is liable for
all pre-distribution taxes attributable to its business, and we generally
indemnify Allergan for all unpaid pre-distribution taxes attributable to our
business for the current taxable year. In addition, the tax sharing agreement
provides that Allergan is generally liable for taxes that are incurred as a
result of restructuring activities undertaken to effectuate the distribution.

We and Allergan have made representations to each other and to the Internal
Revenue Service in connection with the private letter ruling that Allergan has
received regarding the tax-free nature of the distribution of our common stock
by Allergan to its stockholders. If either we or Allergan breach our
representations to each other or to the Internal Revenue Service, or if we or
Allergan take or fail to take, as the case may be, actions that result in the
distribution failing to meet the requirements of a tax-free distribution
pursuant to Section 355 of the Internal Revenue Code, the party in breach will
indemnify the other party for any and all resulting taxes.

CRITICAL ACCOUNTING POLICIES

Revenue and Accounts Receivable

We recognize revenue from product sales when the goods are shipped and title
and risk of loss transfer to the customer (i.e., F.O.B. shipping point), with
the exception of intraocular lenses, which are generally distributed on a
consignment basis and recognized as revenue upon implantation in a patient. We
generally permit returns of product from any product line by any class of
customer if the product is returned in a timely manner, in good condition, and
through the normal channels of

17



---



##### Table of Contents



Advanced Medical Optics, Inc.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS FOR THE QUARTER ENDED JUNE 28, 2002

CRITICAL ACCOUNTING POLICIES (Continued)

distribution. Return policies in certain international markets can be more
stringent and are based on the terms of contractual agreements with customers.
Allowances for returns are provided for based upon an analysis of our
historical patterns of returns matched against the sales from which they
originated. Historically, product returns have been within the amounts
reserved.

The allowance for doubtful accounts is determined by analyzing specific
customer accounts and assessing the risk of uncollectibility based on
insolvency, disputes or other collection issues. In addition, we routinely
analyze the different receivable aging categories and establish reserves based
on the length of time receivables are past due.

Inventories

Inventories are valued at the lower of first-in, first-out cost or market. On
a regular basis, we evaluate inventory balances for excess quantities and
obsolescence by analyzing estimated demand, inventory on hand, sales levels and
other information. Inventory balances are reduced, if necessary, based on the
analysis.

RESULTS OF OPERATIONS

Net Sales. The following table compares net sales by product line for the three
month and six month periods ended June 28, 2002 and June 29, 2001:

|                    |  |                    |         |                  |  |          |         |          |  |   |         |   |  |   |         |  
|------------------- |  | ------------------ | ------- | ---------------- |  | -------- | ------- | -------- |  | - | ------- | - |  | - | ------- | -
|                    |  | Three Months Ended |         | Six Months Ended
|                    |  |                    |         |                 
|                    |  | June 28,           |         | June 29,         |  | June 28, |         | June 29,
|(in thousands)      |  | 2002               |         | 2001             |  | 2002     |         | 2001    
|                    |  |                    |         |                  |  |          |         |         
|Ophthalmic Surgical |  | $                  | 70,901  |                  |  | $        | 65,526  |          |  | $ | 128,313 |   |  | $ | 122,218 |  
|Contact Lens Care   |  |                    | 66,777  |                  |  |          | 73,682  |          |  |   | 123,363 |   |  |   | 137,801 |  
|                    |  |                    |         |                  |  |          |         |          |  |   |         |   |  |   |         |  
|Total Net Sales     |  | $                  | 137,678 |                  |  | $        | 139,208 |          |  | $ | 251,676 |   |  | $ | 260,019 |  
|                    |  |                    |         |                  |  |          |         |          |  |   |         |   |  |   |         |  
|Domestic            |  |                    | 29.0    | %                |  |          | 30.6    | %        |  |   | 29.7    | % |  |   | 31.6    | %
|International       |  |                    | 71.0    | %                |  |          | 69.4    | %        |  |   | 70.3    | % |  |   | 68.4    | %

Net sales decreased $1.5 million, or 1.1%, to $137.7 million in the three
months ended June 28, 2002 from $139.2 million in the three months ended June
29, 2001. Net sales for the six months ended June 28, 2002 were $251.7
million, a 3.2% decrease from the comparable 2001 amount.

The impact of foreign currency changes compared to the comparable prior year
periods increased net sales by $0.1 million, or 0.1%, and decreased net sales
by $5.6 million, or 2.2%, for the three and six months ended June

18



---



##### Table of Contents



Advanced Medical Optics, Inc.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS FOR THE QUARTER ENDED JUNE 28, 2002

RESULTS OF OPERATIONS (Continued)

28, 2002, respectively. At constant currency rates, net sales decreased $1.6
million, or 1.2%, and decreased $2.7 million, or 1.0%, for the three and six
months ended June 28, 2002, respectively, compared with the same periods last
year. The total decrease in net sales in the three and six months ended June
28, 2002 compared with the same periods last year was primarily the result of a
decrease in sales of contact lens care products, partially offset by an
increase in sales of our ophthalmic surgical products.

Global sales of our contact lens care products decreased $6.9 million, or 9.4%,
and decreased $14.4 million, or 10.5%, in the three and six months ended June
28, 2002, respectively, as compared with the same periods last year. Sales of
our contact lens care products in the United States decreased $3.3 million, or
20.1%, and decreased $9.0 million, or 26.6%, in the three and six months ended
June 28, 2002, respectively, compared with the same periods last year,
primarily due to a decrease in sales of private-label cold-chemical one-bottle
disinfection systems. International sales of our contact lens care products
decreased $3.6 million, or 6.3%, and decreased $5.4 million, or 5.3%, in the
three and six months ended June 28, 2002, respectively, compared with the same
periods last year. The decrease in the six months ended June 28, 2002 was
partially a result of the weakening of foreign currencies, primarily the
Japanese yen and euro, versus the dollar, which accounted for $3.5 million of
the decrease in international sales. At constant currency rates, international
contact lens care sales in the three and six months ended June 28, 2002
decreased $3.6 million, or 6.3%, and decreased $2.0 million, or 1.9%,
respectively.

The overall decreases in net sales for the three and six months ended June 28,
2002 are primarily attributable to managements strategic decision to exit the
low-margin private label business. Excluding the results of the private label
business from all periods, contact lens care sales were materially unchanged.
We expect that our global sales of contact lens care products will continue to
contract as customers continue to increase their use of lower priced one-bottle
cold-chemical disinfection systems and decrease their use of peroxide-based
disinfection systems. As our mix of products shifts towards one-bottle
disinfection systems, we expect that this trend will have a diminishing impact
on our sales.

Global sales of our ophthalmic surgical products increased $5.4 million, or
8.2%, and increased $6.1 million, or 5.0%, in the three and six months ended
June 28, 2002, respectively, compared with the same periods last year. In the
United States, sales of our ophthalmic surgical products increased $0.6
million, or 2.0%, and increased $1.5 million, or 3.0%, in the three and six
months ended June 28, 2002, respectively, compared with the same periods last
year. International sales of our ophthalmic surgical products increased $4.8
million, or 12.4%, and increased $4.6 million, or 6.3%, in the three and six
months ended June 28, 2002, respectively, compared with the same periods last
year. Sales in the United States

19



---



##### Table of Contents



Advanced Medical Optics, Inc.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS FOR THE QUARTER ENDED JUNE 28, 2002

RESULTS OF OPERATIONS (Continued)

increased primarily due to an increase in sales of phacoemulsification
equipment. International sales of our ophthalmic surgical products in the six
months ended June 28,2002 were negatively impacted primarily by the weakening
of the Japanese yen and the euro versus the dollar, which resulted in a $2.1
million, or 1.7%, unfavorable currency impact. At constant currency rates,
international sales of our ophthalmic surgical products for the three and six
months ended June 28, 2002, increased $4.7 million, or 12.0%, and increased
$6.7 million, or 9.3%, respectively. The
increases were primarily attributable to sales increases in phacoemulsification
equipment and the SENSAR acrylic intraocular lens, offset in part by sales
decreases in PMMA intraocular lenses and silicone intraocular lenses. We
believe that global sales of ophthalmic surgical products will continue to grow
if sales of higher margin foldable intraocular lenses, most notably the SENSAR
acrylic lens, continue to improve.

Gross Margin. Our gross margin was 61.2% of net sales in the three months
ended June 28, 2002, which was unchanged from a year ago. Our gross margin
increased as a percent of net sales by 1.3 percentage points from 59.9% in the
six months ended June 29, 2001 to 61.2% in the six months ended June 28, 2002.
Our gross margin in the three and six months ended June 28, 2002 was negatively
impacted by the write-off of $2.6 million of inventory deemed unusable due to
our spin-off from Allergan. Excluding this write-off, gross margin as a
percent of net sales would have been 63.1% and 62.2% in the three and six
months ended June 28, 2002, respectively. The increase in gross margin as a
percent of net sales was primarily the result of higher gross margins achieved
on sales of contact lens care products and a change in product sales mix to
higher margin surgical products. Gross margin in dollars declined by $1.0
million and $1.8 million in the three and six months ended June 28, 2002,
respectively, compared with the same periods last year, due to the decrease in
net sales and the write-off of inventory, partially offset by the increase in
gross margin percentage.

Selling, general and administrative. Selling, general and administrative
expenses were $59.6 million, or 43.3% of net sales, and $113.8 million, or
45.2% of net sales, in the three and six months ended June 28, 2002,
respectively, compared to $58.5 million, or 42.0% of net sales, and $120.6
million, or 46.4% of net sales, in the three and six months ended June 29,
2001, respectively. The increase in both selling, general and administrative
dollars and as a percent of net sales in the three months ended June 28, 2002
as compared to the same period last year was primarily a result of increased
general and administrative expenses incurred in preparation for our spin-off
from Allergan. This was partially offset by reduced selling expenses due to
the lower combined net sales and cost improvements primarily in Europe
resulting from a restructuring of our sales force completed in 2001 and a
reduction in goodwill amortization of $2.2 million. The decrease in both
selling, general and administrative

20



---



##### Table of Contents



Advanced Medical Optics, Inc.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS FOR THE QUARTER ENDED JUNE 28, 2002

RESULTS OF OPERATIONS (Continued)

dollars and as a percent of net sales in the six months ended June 28, 2002 as
compared to the same period last year was primarily a result of lower selling
expenses and a reduction in goodwill amortization of $4.5 million partially
offset by increased general and administrative expenses incurred in preparation
for our spin-off. Beginning in 2002, we no longer amortize goodwill in
accordance with SFAS No. 142.

Research and development. Research and development expenses were $7.9 million,
or 5.7% of net sales, and $14.9 million, or 5.9% of net sales, in the three and
six months ended June 28, 2002, respectively, compared to $7.2 million, or 5.2%
of net sales, and $14.4 million, or 5.6% of net sales, in the three and six
months ended June 29, 2001, respectively. The increase in both research and
development dollars and as a percent of net sales was a result of an increase
in spending for research efforts in the ophthalmic surgical business, partially
offset by a small decrease in research and development spending for the contact
lens care business.

Operating income. Operating income was $16.8 million, or 12.2% of net sales,
and $25.3 million, or 10.1% of net sales, in the three and six months ended
June 28, 2002, respectively, compared to $19.6 million, or 14.1% of net sales,
and $20.7 million, or 8.0% of net sales, in the three and six months ended
June 29, 2001, respectively. The decrease in operating income in the three
months ended June 28, 2002 as compared to the same period last year was
primarily the result of the decrease in gross margin and higher general and
administrative expenses, partially offset by lower selling expenses. The
increase in operating income in the six months ended June 28, 2002 as compared
to the same period last year was primarily the result of the lower selling,
general and administrative expenses, partially offset by a decrease in gross
margin.

Non-operating expense. Non-operating expense was $6.2 million and $7.1 million
in the three and six months ended June 28, 2002, respectively, compared to $1.2
million and $0.7 million in the three and six months ended June 29, 2001,
respectively. We recorded an unrealized loss on derivative instruments of $1.9
million in the six months ended June 28, 2002 compared to an unrealized gain of
$1.0 million in the six months ended June 29, 2001. We record as unrealized
loss/(gain) on derivative instruments the mark to market adjustments on the
outstanding foreign currency options which we enter into, as part of Allergans
overall risk management strategy, to reduce the volatility of expected earnings
in currencies other than U.S. dollar. Additionally, the three and six months
ended June 28, 2002 include early debt extinguishment costs of $3.5 million
associated with the prepayment of debt in Japan. Interest expense increased
$0.6 million and $0.5 million in the three and six months ended June 28, 2002,
respectively, compared with the same periods last year due primarily to the
$300.0 million of debt incurred in late June 2002.

21



---



##### Table of Contents



Advanced Medical Optics, Inc.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS FOR THE QUARTER ENDED JUNE 28, 2002

RESULTS OF OPERATIONS (Continued)

Income taxes. The effective tax rate for the three and six months ended June
28, 2002 was 38.0%, as compared to the effective tax rate of 29.5% and 29.3%
for the three and six months ended June 29, 2001, respectively. The annual
effective tax rate in 2001 included the recognition of certain tax benefits
associated with the utilization of a net operating loss carryforward and the
realization of other deferred tax assets in Japan for which we previously had
established a valuation allowance. In 2001, we
determined, based solely on our judgment, that realization of the deferred tax
assets had become more likely than not and accordingly, we reversed
the valuation allowance previously established. We do not anticipate that our
future provision for income taxes will include tax benefits similar to those we
recognized in 2001. We believe our future effective income tax rate may vary
depending on our mix of domestic and international taxable income or loss and
the various tax and treasury methodologies that we implement, including a
determination of our policy regarding repatriation of future accumulated
foreign earnings.

Net earnings. Net earnings for the three and six months ended June 28, 2002
were $6.6 million and $11.3 million, respectively, compared to $12.9 million
and $13.8 million in the three and six months ended June 29, 2001,
respectively. The $6.4 million decrease in net earnings for the three months
ended June 28, 2002 is primarily the result of the $2.8 million decrease in
operating income and the increase in non-operating expense partially offset by
the decrease in the provision for income taxes. The
$2.5 million decrease in net earnings for the six months ended June 28, 2002 is
primarily the result of the increase in non-operating expenses and the increase
in the provision for income taxes partially offset by the increase in operating
income. Net earnings for the six months ended June 29, 2001 included a $0.4
million after-tax loss related to the adoption of SFAS No. 133  Accounting
for Derivative Instruments and Hedging Activities.

LIQUIDITY AND CAPITAL RESOURCES

Management assesses our liquidity by our ability to generate cash to fund
operations. Significant factors in the management of liquidity are: funds
generated by operations; levels of accounts receivable, inventories, accounts
payable and capital expenditures; adequate lines of credit; and financial
flexibility to attract long-term capital on satisfactory terms.

Historically, we have generated cash from operations in excess of working
capital requirements, and we expect to do so in the future. The net cash
provided by operating activities was $40.1 million in the six months ended June
28, 2002 compared to $16.5 million in six months ended June 29, 2001. Operating
cash flow increased in the six months ended June 28, 2002 compared to the six
months ended June 29, 2001 primarily as a result of improved management of
trade receivables and inventory and an increase in

22



---



##### Table of Contents



Advanced Medical Optics, Inc.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS FOR THE QUARTER ENDED JUNE 28, 2002

LIQUIDITY AND CAPITAL RESOURCES (Continued)

accrued expenses and other liabilities, partially offset by a lower net
earnings and a decrease in accounts payable.

Net cash used in investing activities was $12.3 million and $5.2 million in the
six months ended June 28, 2002 and June 29, 2001, respectively. Expenditures
for property, plant and equipment totaled $8.7 million and
$1.6 million in the six months ended June 28, 2002 and June 29, 2001,
respectively. These expenditures included expansion of manufacturing
facilities, improvements to our recently leased headquarters in 2002 and a
variety of other projects designed to improve productivity. We expect to
invest a total of $10 million to $15 million in property, plant and equipment
in 2002. Expenditures for demonstration (demo) and bundled equipment,
primarily phacoemulsification and microkeratome surgical equipment, were $2.7
million and $2.3 million in the six months ended June 28, 2002 and June 29,
2001, respectively. We maintain demo and bundled equipment to facilitate
future sales of similar equipment and related products to our customers. In
addition to the property, plant and equipment expenditures, we expect to invest
a total of $4.0 million to $5.0 million in demo and bundled equipment in 2002.
Expenditures for capitalized internal-use software were $0.9 million and $1.2
million in the six months ended June 28, 2002 and June 29, 2001, respectively.
We expect to invest a total of $5.0 million to $7.0 million in capitalized
internal-use software in 2002.

Net cash provided by financing activities was $47.6 million in the six months
ended June 28, 2002, which was comprised of $305.6 million of long-term debt
borrowings partially offset by long-term debt repayments of $111.4 million and
$146.6 million of distributions to Allergan, net of advances. Net cash used in
financing activities was $18.7 million in the six months ended June 29, 2001,
which was comprised of distributions to Allergan, net of advances. Net
transfers to Allergan have ceased as a result of the spin-off.

As of the distribution date, we had incurred $300.0 million of debt with an
estimated weighted average interest rate of 6.89%, including the benefit of
interest rate swaps, resulting in incremental annual interest expense of
approximately $18.8 million at current interest rates. As a result, we expect a
significant decrease in our cash flows from operations. We used approximately
$258.1 million of these credit facilities to repay indebtedness borrowed from
Allergan to purchase various assets from Allergan, make a distribution to
Allergan in exchange for various assets contributed to us and repay a portion
of Allergans debt assumed by us in connection with the spin-off. We also
entered into a new $35.0 million revolving credit facility to fund future
capital expenditures and working capital, if needed. Currently, approximately
$17.0 million of the $35.0 million revolving credit facility has been reserved
to support letters of credit issued on our behalf.

23



---



##### Table of Contents



Advanced Medical Optics, Inc.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS FOR THE QUARTER ENDED JUNE 28, 2002

LIQUIDITY AND CAPITAL RESOURCES (Continued)

Historically, a majority of our international and domestic cash accounts were
linked to Allergans centralized cash management system. Accordingly, a
majority of cash generated from operations has been transferred to Allergan.
The net effect of these cash transfers has been reflected in the Allergan,
Inc. net investment account as shown in the equity section of our unaudited
condensed combined balance sheets.

Our cash position includes amounts denominated in foreign currencies, and the
repatriation of those cash balances from some of our non-U.S. subsidiaries
could result in additional tax costs. However, these cash balances are
generally available without legal restriction to fund ordinary business
operations.

We believe that the net cash provided by our operating activities, supplemented
as necessary with borrowings available under our new revolving credit facility
and existing cash and equivalents, will provide sufficient resources to meet
our working capital requirements, debt service and other cash needs over the
next year.

We are dependent, in part, upon the reimbursement policies of government and
private health insurance companies. Government and private sector initiatives
to limit the growth of health care costs, including price regulation and
competitive pricing, are continuing in many countries where
we do business. As a result of these changes, the marketplace has placed
increased emphasis on the delivery of more cost-effective medical therapies.
While we have been unaware of significant price resistance resulting from the
trend toward cost containment, changes in reimbursement policies and other
reimbursement methodologies and payment levels could have an adverse effect on
our pricing flexibility.

Additionally, the current trend among hospitals and other customers of medical
device manufacturers is to consolidate into larger purchasing groups to enhance
purchasing power. The enhanced purchasing power of these larger customers may
also increase the pressure on product pricing, although we are unable to
estimate the potential impact at this time.

Inflation. Although at reduced levels in recent years, inflation continues to
apply upward pressure on the cost of goods and services used by us. The
competitive and regulatory environments in many markets substantially limit our
ability to fully recover these higher costs through increased selling prices.
We continually seek to mitigate the adverse effects of inflation through cost
containment and improved productivity and manufacturing processes.

Foreign currency fluctuations. Approximately 70% of our revenues for the six
months ended June 28, 2002 were derived from operations outside the

24



---



##### Table of Contents



Advanced Medical Optics, Inc.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS FOR THE QUARTER ENDED JUNE 28, 2002

LIQUIDITY AND CAPITAL RESOURCES (Continued)

United States and a significant portion of our cost structure is denominated in
currencies other than the U.S. dollar. Therefore, we are subject to
fluctuations in sales and earnings reported in U.S. dollars as a result of
changing currency exchange rates.

The impact of foreign currency fluctuations on sales was a $0.1 million
increase and a $5.6 million decrease for the three and six months ended

June 28, 2002, respectively, and a $10.0 million decrease and a $16.7 million
decrease for the three and six months ended June 29, 2001, respectively. The
2002 and 2001 sales decreases were due primarily to a weakening of the Japanese
yen and European currencies.

Contractual obligations. The following represents a list of our contractual
obligations and commitments as of June 28, 2002:

|                  |  |                      |     |      |  |      |     |      |  |      |     |            |  |               |     |  |  |  |      |  |  |  |       |  |  |   |       | 
|----------------- |  | -------------------- | --- | ---- |  | ---- | --- | ---- |  | ---- | --- | ---------- |  | ------------- | --- |  |  |  | ---- |  |  |  | ----- |  |  | - | ----- | 
|                  |  | Payments Due by Year |    
|                  |  |                      |    
|                  |  | 2003                 |     | 2004 |  | 2005 |     | 2006 |  | 2007 |     | Thereafter |  | Total        
|                  |  |                      |     |      |  |      |     |      |  |      |     |            |  |              
|                  |  |                      |     |      |  |      |     |      |  |      |     |            |  | (in millions) |     |  |  |  |      |  |  | 
|Long-term debt    |  | $                    | 1.0 |      |  |      | 1.0 |      |  |      | 1.0 |            |  |               | 1.0 |  |  |  | 48.0 |  |  |  | 248.0 |  |  | $ | 300.0 | 
|Lease obligations |  | $                    | 6.8 |      |  |      | 4.5 |      |  |      | 3.8 |            |  |               | 3.9 |  |  |  | 2.4  |  |  |  | 18.4  |  |  | $ | 39.8  | 

25



---



##### Table of Contents






ADVANCED MEDICAL OPTICS

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

In the normal course of business, our operations are exposed to risks
associated with fluctuations in interest rates and foreign currency exchange
rates. For all periods presented, we were considered in Allergans overall risk
management strategy. As part of this strategy, Allergan managed its risks based
on managements judgment of the appropriate trade-off between risk, opportunity
and costs. With respect to our risks, Allergan primarily utilized foreign
currency option and forward contracts to economically hedge or reduce these
exposures. As a stand-alone company, we will routinely monitor our risks
associated with fluctuations in currency exchange rates and interest rates. We
will address these risks through controlled risk management that includes the
use of derivative financial instruments to economically hedge or reduce these
exposures. We do not expect to enter into financial instruments for trading or
speculative purposes.

To ensure the adequacy and effectiveness of our interest rate and foreign
exchange hedge positions, we will continually monitor, from an accounting and
economic perspective, our interest rate swap positions and foreign exchange
forward and option positions both on a stand-alone basis and in conjunction
with our underlying interest rate and foreign currency exposures.

However, given the inherent limitations of forecasting and the anticipatory
nature of the exposures intended to be hedged, there can be no assurance that
such programs will offset more than a portion of the adverse financial impact
resulting from unfavorable movements in either interest or foreign exchange
rates. In addition, the timing of the accounting for recognition of gains and
losses related to mark-to-market instruments for any given period may not
coincide with the timing of gains and losses related to the underlying economic
exposures and, therefore, may adversely affect our operating results and
financial position. Our allocated portion of the gains and losses realized from
the foreign currency forward and option contracts are recorded in Other, net
in the accompanying unaudited condensed combined statements of earnings. The
allocation of such gains and losses is based on our net sales compared to total
Allergan net sales.

Interest rate risk. Prior to the spin-off from Allergan, our interest expense
has been more sensitive to fluctuations in the general level of Japan interest
rates than to changes in rates in other markets as the majority of our
borrowings were in Japan. Our $300.0 million of new debt is comprised solely of
domestic borrowings. Thus, our interest expense will fluctuate with rate
changes in the U.S.

We have entered into various interest rate swap agreements which effectively
convert our interest rate on $150.0 million of the senior subordinated notes
from a fixed rate to a floating rate and convert the

26



---



##### Table of Contents



Advanced Medical Optics

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK (continued)

interest rate on $50.0 million of our $100.0 million term credit facility from
a floating rate to a fixed rate. At June 28, 2002, the fair value of $(2.0)
million of the interest rate swap agreements related to the senior
subordinated notes is recorded in Other liabilities
in the accompanying condensed combined balance sheet.

If interest rates were to increase or decrease by 0.125% for the year, annual
interest expense would increase or decrease by approximately $250,000.

The tables below presents information about our cash equivalents and our debt
obligations as of June 28, 2002 and December 31, 2001:

June 28, 2002

|                               |  |                                       |       |      |  |      |       |        |  |      |       |            |  |       |       |       |  |   |        |   |  |   |         |   |  |   |         |   |  |   |         |  
|------------------------------ |  | ------------------------------------- | ----- | ---- |  | ---- | ----- | ------ |  | ---- | ----- | ---------- |  | ----- | ----- | ----- |  | - | ------ | - |  | - | ------- | - |  | - | ------- | - |  | - | ------- | -
|                               |  | Maturing in                           |       |      |  |      |       | Fair  
|                               |  |                                       |       |      |  |      |       | Market
|                               |  | 2003                                  |       | 2004 |  | 2005 |       | 2006   |  | 2007 |       | Thereafter |  | Total |       | Value
|                               |  |                                       |       |      |  |      |       |        |  |      |       |            |  |       |       |      
|                               |  | (in thousands, except interest rates)
|LIABILITIES                    |  |                                       |       |      |  |      |       |        |  |      |       |            |  |       |       |       |  |   |        |   |  |   |         |   |  |   |         |   |  |   |         |  
|Debt Obligations:              |  |                                       |       |      |  |      |       |        |  |      |       |            |  |       |       |       |  |   |        |   |  |   |         |   |  |   |         |   |  |   |         |  
|Fixed Rate                     |  | $                                     |      |      |  | $    |      |        |  | $    |      |            |  | $     |      |       |  | $ |       |   |  | $ | 200,000 |   |  | $ | 200,000 |   |  | $ | 197,000 |  
|Weighted Average
Interest Rate |  |                                       |       |      |  |      |       |        |  |      |       |            |  |       |       |       |  |   |        |   |  |   | 9.25    | % |  |   | 9.25    | % |  |   |         |  
|Variable Rate                  |  |                                       | 1,000 |      |  |      | 1,000 |        |  |      | 1,000 |            |  |       | 1,000 |       |  |   | 48,000 |   |  |   | 48,000  |   |  |   | 100,000 |   |  | $ | 100,000 |  
|Weighted Average
Interest Rate |  |                                       | 5.11  | %    |  |      | 5.11  | %      |  |      | 5.11  | %          |  |       | 5.11  | %     |  |   | 5.11   | % |  |   | 5.11    | % |  |   | 5.11    | % |  |   |         |  
|Total Debt Obligations         |  | $                                     | 1,000 |      |  | $    | 1,000 |        |  | $    | 1,000 |            |  | $     | 1,000 |       |  | $ | 48,000 |   |  | $ | 248,000 |   |  | $ | 300,000 |   |  | $ | 297,000 |  
|Weighted Average
Interest Rate |  |                                       | 5.11  | %    |  |      | 5.11  | %      |  |      | 5.11  | %          |  |       | 5.11  | %     |  |   | 5.11   | % |  |   | 8.45    | % |  |   | 7.87    | % |  |   |         |  
|INTEREST RATE DERIVATIVES      |  |                                       |       |      |  |      |       |        |  |      |       |            |  |       |       |       |  |   |        |   |  |   |         |   |  |   |         |   |  |   |         |  
|Interest Rate Swaps:           |  |                                       |       |      |  |      |       |        |  |      |       |            |  |       |       |       |  |   |        |   |  |   |         |   |  |   |         |   |  |   |         |  
|Fixed to Variable              |  | $                                     |      |      |  | $    |      |        |  | $    |      |            |  | $     |      |       |  | $ |       |   |  | $ | 150,000 |   |  | $ | 150,000 |   |  | $ | (2,028  | )
|Average Pay Rate               |  |                                       |      |      |  |      |      |        |  |      |      |            |  |       |      |       |  |   |       |   |  |   | 6.04    | % |  |   | 6.04    | % |  |   |         |  
|Average Receive Rate           |  |                                       |      |      |  |      |      |        |  |      |      |            |  |       |      |       |  |   |       |   |  |   | 9.25    | % |  |   | 9.25    | % |  |   |         |  

December 31, 2001

|                               |  |                                       |        |      |  |      |        |        |  |      |   |            |  |       |        |       |  |  |   |  |  |  |   |  |  |   |        |   |  |   |        | 
|------------------------------ |  | ------------------------------------- | ------ | ---- |  | ---- | ------ | ------ |  | ---- | - | ---------- |  | ----- | ------ | ----- |  |  | - |  |  |  | - |  |  | - | ------ | - |  | - | ------ | 
|                               |  | Maturing in                           |        |      |  |      |        | Fair  
|                               |  |                                       |        |      |  |      |        | Market
|                               |  | 2002                                  |        | 2003 |  | 2004 |        | 2005   |  | 2006 |   | Thereafter |  | Total |        | Value
|                               |  |                                       |        |      |  |      |        |        |  |      |   |            |  |       |        |      
|                               |  | (in thousands, except interest rates)
|ASSETS                         |  |                                       |        |      |  |      |        |        |  |      |   |            |  |       |        |       |  |  |   |  |  |  |   |  |  |   |        |   |  |   |        | 
|Cash Equivalents:              |  |                                       |        |      |  |      |        |        |  |      |   |            |  |       |        |       |  |  |   |  |  |  |   |  |  |   |        |   |  |   |        | 
|Repurchase Agreements          |  | $                                     | 6,725  |      |  |      |       |        |  |      |  |            |  |       |       |       |  |  |  |  |  |  |  |  |  | $ | 6,725  |   |  | $ | 6,725  | 
|Weighted Average
Interest Rate |  |                                       | 1.59   | %    |  |      |       |        |  |      |  |            |  |       |       |       |  |  |  |  |  |  |  |  |  |   | 1.59   | % |  |   |        | 
|LIABILITIES                    |  |                                       |        |      |  |      |        |        |  |      |   |            |  |       |        |       |  |  |   |  |  |  |   |  |  |   |        |   |  |   |        | 
|Debt Obligations:              |  |                                       |        |      |  |      |        |        |  |      |   |            |  |       |        |       |  |  |   |  |  |  |   |  |  |   |        |   |  |   |        | 
|Fixed Rate (JPY)               |  |                                       |       |      |  | $    | 18,988 |        |  |      |  |            |  | $     | 37,830 |       |  |  |  |  |  |  |  |  |  | $ | 56,818 |   |  | $ | 59,063 | 
|Weighted Average Interest Rate |  |                                       |       |      |  |      | 3.55   | %      |  |      |  |            |  |       | 1.85   | %     |  |  |  |  |  |  |  |  |  |   | 2.42   | % |  |   |        | 
|Variable Rate (JPY)            |  |                                       | 18,988 |      |  |      | 18,991 |        |  |      |  |            |  |       |       |       |  |  |  |  |  |  |  |  |  |   | 37,979 |   |  |   | 37,979 | 
|Weighted Average Interest Rate |  |                                       | 0.75   | %    |  |      | 0.58   | %      |  |      |  |            |  |       |       |       |  |  |  |  |  |  |  |  |  |   | 0.66   | % |  |   |        | 
|Total Debt Obligations         |  | $                                     | 18,988 |      |  | $    | 37,979 |        |  |      |  |            |  | $     | 37,830 |       |  |  |  |  |  |  |  |  |  | $ | 94,797 |   |  | $ | 97,042 | 
|Weighted Average Interest Rate |  |                                       | 0.75   | %    |  |      | 2.06   | %      |  |      |  |            |  |       | 1.85   | %     |  |  |  |  |  |  |  |  |  |   | 1.71   | % |  |   |        | 

Foreign currency risk. Overall, we are a net recipient of currencies other
than the U.S. dollar and, as such, we benefit from a weaker dollar and are
adversely affected by a stronger dollar relative to major currencies worldwide.
Accordingly, changes in exchange rates, and in particular a

27



---



##### Table of Contents



Advanced Medical Optics

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK (continued)

strengthening of the U.S. dollar, may negatively affect our consolidated sales
and gross margins as expressed in U.S. dollars.

From time to time Allergan, with respect to our currency risks, has entered
into foreign currency option and foreign currency forward contracts to reduce
earnings and cash flow volatility associated with foreign exchange rate changes
to allow our management to focus its attention on its core business issues and
challenges. Through the end of 2002 and as part of the transitional services
agreement, we will bear the costs and receive the benefits of Yen denominated
foreign currency option contracts entered into by Allergan.

As a stand-alone company, we plan to enter into various contracts which change
in value as foreign exchange rates change to economically offset the effect of
changes in the value of foreign currency assets and liabilities, commitments
and anticipated foreign currency denominated sales and operating expenses. Our
policy will be to enter into foreign currency option and foreign currency
forward contracts in amounts between minimum and maximum anticipated foreign
exchange exposures, generally for periods not to exceed one year.

NEW ACCOUNTING STANDARDS

In April 2002, Statement of Financial Accounting Standards No. 145, Rescission
of FASB Statements No. 4, 44, and 64, Amendment of FASB Statement No. 13, and
Technical Corrections (SFAS No. 145) was issued. SFAS No. 145 rescinds SFAS
No. 4, which required all gains and losses from extinguishment of debt to be
aggregated and, if material, classified as an extraordinary item, net of
related income tax effect. Upon adoption of SFAS No. 145, we will be required
to apply the criteria in APB Opinion No. 30, Reporting the Results of
Operations  Reporting the Effects of Disposal of a Segment of a Business, and
Extraordinary, Unusual and Infrequently Occurring Events and Transactions
(Opinion No. 30), in determining the classification of gains and losses
resulting from the extinguishment of debt. SFAS No. 145 is effective for
annual years beginning after May 15, 2002, with earlier adoption encouraged.
We have elected to early-adopt SFAS No. 145 during the quarter ended June 28,
2002. The adoption of SFAS 145 did not have a material effect on our combined
financial statements.

In July 2002, Statement of Financial Accounting Standards No. 146, Accounting
for Costs Associated with Exit or Disposal Activities (SFAS No. 146) was
issued. SFAS No. 146 requires companies to recognize costs associated with
exit or disposal activities when they are incurred rather than at the date of a
commitment to an exit or disposal plan. Examples of costs covered by the
standard include lease termination costs and certain employee severance costs
that are associated with a restructuring, discontinued operation, plant
closing, or other exit or disposal activity. SFAS No. 146 is effective
prospectively for exit or disposal activities initiated after December 31,
2002, with earlier adoption encouraged. As the provisions of SFAS No. 146 are
required to be applied prospectively

28



---



##### Table of Contents



Advanced Medical Optics

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK (continued)

after the adoption date, we cannot determine the potential effects that
adoption of SFAS No. 146 will have on our combined financial statements.

29



---



##### Table of Contents






Advanced Medical Optics, Inc.

CERTAIN FACTORS AND TRENDS AFFECTING AMO AND ITS BUSINESSES

Certain statements made by the Company in this report and in other reports and
statements released by the Company constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995,
such as comments which express the Companys opinions about trends and factors
which may impact future operating results. Disclosures which use words such as
the Company believes, anticipates, expects and similar expressions are
intended to identify forward-looking statements. Such statements are subject
to certain risks and uncertainties that could cause actual results to differ
materially from opinions and expectations. Any such forward-looking
statements, whether made in this report or elsewhere, should be considered in
context with the various disclosures made by the Company about its businesses
including, without limitation, the factors discussed below:

Risks Related to Our Separation from Allergan

OUR HISTORICAL FINANCIAL INFORMATION MAY NOT BE REPRESENTATIVE OF WHAT OUR
HISTORICAL RESULTS AS AN INDEPENDENT COMPANY WOULD HAVE BEEN AND, THEREFORE,
MAY NOT BE INDICATIVE OF OUR FUTURE RESULTS.

The historical combined financial information we have included in this report
may not reflect what our results of operations, financial position and cash
flows would have been had we been an independent company during the periods
presented or what our results of operations, financial position and cash flows
will be in the future. We were not operated as a separate company, subsidiary,
division or segment by Allergan during the historical periods presented and our
historical combined financial statements reflect allocations for services
provided to us by Allergan. These allocations will differ from the costs we
will incur for these services as an independent company. Additionally, our
historical combined financial statements do not reflect fundamental changes
that we expect to occur in the future as a result of our separation from
Allergan, including changes in our capital structure. Our historical effective
tax rate may not be indicative of our future effective tax rate due to changes
in the mix of our earnings in the various countries where we operate.
Therefore, our historical combined financial statements will not be indicative
of our future performance as an independent company.

We have not made adjustments to our historical financial information to reflect
changes that will occur in our cost structure, financing and operations as a
result of our separation from Allergan. These changes include potentially
increased costs associated with reduced economies of scale. For example, our
separation from Allergan may result in dislocations to our organization and
personnel structure, and will also result in the duplication of some
administrative and managerial personnel and other expenses required for the
operation of independent companies. Our historical financial information does
not reflect any increased costs associated with being a publicly traded,
independent company.

30



---



##### Table of Contents



Advanced Medical Optics, Inc.

CERTAIN FACTORS AND TRENDS AFFECTING AMO AND ITS BUSINESSES (continued)

WE HAVE NO HISTORY OPERATING AS AN INDEPENDENT COMPANY UPON WHICH YOU CAN
EVALUATE US.

We do not have an operating history as a stand-alone entity. Prior to the
separation, the optical medical device business was operated by Allergan as a
part of its broader corporate organization rather than as a stand-alone
company. Following the distribution, our ability to satisfy our obligations and
maintain profitability is solely dependent upon the future performance of the
businesses we own and operate and we will not be able to rely upon the capital
resources and cash flows of those business lines remaining with Allergan.
Historically, Allergan performed all corporate functions for us, including the
following:



| |  |  | information and technology services;                                                   
| | - |  | ---------------------------------------------------------------------------------------
|
| |  |  | legal functions;                                                                       
|
| |  |  | public and investor relations;                                                         
|
| |  |  | treasury administration;                                                               
|
| |  |  | employee compensation and benefits administration;                                     
|
| |  |  | insurance administration;                                                              
|
| |  |  | accounting functions;                                                                  
|
| |  |  | internal audit;                                                                        
|
| |  |  | corporate income tax administration;                                                   
|
| |  |  | telecommunications;                                                                    
|
| |  |  | facilities services; and                                                               
|
| |  |  | complete operational support in many of the countries in which we
conduct our business.

Following the separation, Allergan has no obligation to provide these functions
to us other than the transitional services that will be provided to us pursuant
to the transitional services agreement with Allergan. If we do not have in
place our own systems and business functions, or if we do not have agreements
with other providers of these services once our transitional services agreement
with Allergan expires, we may not be able to operate our business effectively
and our profitability may decline. In addition, if Allergan does not perform
the transitional services they have agreed to provide us at the same level as
when we were part of Allergan, these services may not be sufficient to meet our
needs and we may not be able to operate our business effectively after the
separation. We are in the process of creating our own, or engaging third

31



---



##### Table of Contents



Advanced Medical Optics, Inc.

CERTAIN FACTORS AND TRENDS AFFECTING AMO AND ITS BUSINESSES (continued)

parties to provide, systems and business functions to replace many of the
systems and business functions Allergan currently provides us. We may not be
successful in implementing these systems and business functions or in
transitioning data from Allergans systems to ours. In addition, we may incur
costs for these functions that are higher than the amounts reflected in our
historical combined financial statements.

WE HAVE A SIGNIFICANT AMOUNT OF DEBT, WHICH WE MIGHT NOT BE ABLE TO SERVICE AND
WHICH CONTAINS COVENANTS THAT LIMIT OUR ACTIVITIES

As a result or our issuance of the senior subordinated notes and entering into
the senior credit facility, we have substantial indebtedness. As of June 28,
2002, we had $300.0 million of indebtedness and had $35.0 million of additional
borrowings available under our senior revolving credit facility, approximately
$17.0 million of which has been reserved to support letters of credit issued on
our behalf. This level of indebtedness could have significant consequences,
including:



| |  |  | limiting cash flow available for working capital, capital
expenditures, acquisitions and other corporate purposes because a
significant portion of our cash flow from operations must be dedicated
to servicing our debt;
| | - |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|
| |  |  | limiting our ability to obtain additional financing in the future for
working capital or other purposes; and                                                                                                             
|
| |  |  | limiting our flexibility to react to competitive or other changes in
our industry, and to economic conditions generally.                                                                                                 

Our ability to repay or refinance our indebtedness will depend upon our future
operating performance, which will be affected by general economic, financial,
competitive, legislative, regulatory and other factors beyond our control.

The indenture relating to the senior subordinated notes and the senior credit
facility contain, and future debt instruments to which we may become subject
may contain, debt covenants that limit our ability to engage in activities that
could otherwise benefit our company, including restrictions on our ability to:



| |  |  | incur additional indebtedness;                                      
| | - |  | --------------------------------------------------------------------
|
| |  |  | create liens;                                                       
|
| |  |  | make investments;                                                   
|
| |  |  | enter into transactions with affiliates;                            
|
| |  |  | sell assets;                                                        
|
| |  |  | declare or pay dividends or other distributions to stockholders; and

32



---



##### Table of Contents



Advanced Medical Optics, Inc.

CERTAIN FACTORS AND TRENDS AFFECTING AMO AND ITS BUSINESSES (continued)



| |  |  | consolidate, merge or transfer all or substantially all of our assets
and the assets of our subsidiaries on a consolidated basis.
| | - |  | ---------------------------------------------------------------------------------------------------------------------------------

Our senior credit facility also requires us to maintain specific leverage and
interest coverage ratios. Our ability to comply with these covenants is
dependent on our future performance, which will be subject to many factors,
some of which are beyond our control, including prevailing economic conditions.

A failure to comply with these covenants could result in a default under our
indebtedness, which could permit the holders to accelerate such indebtedness.
If any of our indebtedness is accelerated, we may not have sufficient funds
available to repay such indebtedness.

OUR ABILITY TO ENGAGE IN ACQUISITIONS AND OTHER STRATEGIC TRANSACTIONS USING
OUR STOCK IS SUBJECT TO LIMITATIONS BECAUSE OF THE FEDERAL INCOME TAX
REQUIREMENTS FOR A TAX-FREE DISTRIBUTION.

For the distribution of our stock by Allergan to qualify as tax-free to
Allergan, there must not be a change in ownership of 50% or more in either the
voting power or value of either our stock or Allergans stock that is
considered to be part of a plan or a series of related transactions associated
with Allergans distribution of our stock to its stockholders. For this
purpose, a change in ownership may include the issuance of our common stock or
Allergans common stock in acquisitions and other similar strategic
transactions. If there are direct or indirect acquisitions of our stock or
Allergans stock by one or more persons during the four-year period beginning
two years prior to and ending two years after the distribution, each such
acquisition may be presumed to be part of a plan or a series of related
transactions associated with Allergans distribution of our stock. If the
cumulative change in ownership from acquisitions presumed to be part of a plan
or a series of related transactions associated with the distribution equates to
50% or more, the distribution may be taxable to Allergan unless the presumption
is rebutted successfully.

Our tax sharing agreement and contribution and distribution agreement with
Allergan may limit our ability to use our stock for acquisitions and other
similar strategic transactions. Under the tax sharing agreement, we may be
required to indemnify Allergan against any corporate level tax on the amount by
which the fair market value of our common stock distributed in the distribution
exceeds Allergans basis in such stock. We are required to meet various
requirements, including obtaining the approval of Allergan, before engaging in
specified transactions that involve the acquisition of our stock or the
issuance of our stock. Many of our competitors are not subject to similar
restrictions and may issue their stock more freely to complete acquisitions,
expand their product offerings and speed the
development of new technology. Therefore, these competitors may have a
competitive advantage over us.

33



---



##### Table of Contents



Advanced Medical Optics, Inc.

CERTAIN FACTORS AND TRENDS AFFECTING AMO AND ITS BUSINESSES (continued)

In addition, while our ability to issue additional equity or engage in
transactions involving a change in ownership of our stock may be constrained,
we are responsible for our own financing. We may determine that it is desirable
to incur debt or issue equity in order to fund our working capital, capital
expenditure and research and development requirements, as well as to make other
investments. If we are unable to engage in such financing transactions within
the constraints of the tax ruling and tax sharing agreement discussed above or
to complete such debt or equity financing, on terms acceptable to us, our
business will be harmed.

WE MAY BE REQUIRED TO SATISFY CERTAIN INDEMNIFICATION OBLIGATIONS TO ALLERGAN,
OR MAY NOT BE ABLE TO COLLECT ON INDEMNIFICATION RIGHTS FROM ALLERGAN.

Under the terms of the contribution and separation agreement, we and Allergan
have each agreed to indemnify each other from and after the distribution with
respect to the indebtedness, liabilities and obligations retained by our
respective companies. These indemnification obligations could be significant.
The ability to satisfy these indemnities if called upon to do so, will depend
upon the future financial strength of each of our companies. We cannot
determine whether we will have to indemnify Allergan for any substantial
obligations after the distribution. We also cannot assure you that if Allergan
has to indemnify us for any substantial obligations, Allergan will have the
ability to satisfy those obligations.

WE MAY BE RESPONSIBLE FOR FEDERAL INCOME TAX LIABILITIES THAT RELATE TO THE
DISTRIBUTION OF OUR COMMON STOCK BY ALLERGAN.

Allergan has received a ruling from the Internal Revenue Service to the effect
that the distribution qualified as a tax-free transaction such that none of the
Allergan stockholders, Allergan or we recognized any income, gain or loss as a
result of the distribution. Allergan and we have made representations and
agreed to certain restrictions on future actions to provide further assurances
that the distribution will continue to qualify as tax-free. If any of the
material facts, representations, and warranties on which the ruling from the
Internal Revenue Service were based are modified or determined not true and
correct, the Internal Revenue Service could challenge the tax-free nature of
the distribution, and unless successfully rebutted, it is possible that the
distribution could be held to be a taxable distribution by Allergan of our
common stock to Allergan stockholders.

If Allergan or we fail to operate under these limitations, or if any of the
facts, representations or warranties made to the Internal Revenue Service were
challenged on audit, and Allergans distribution of our common stock
were ultimately determined not to qualify as tax-free under Section 355 of the
Internal Revenue Code, then in general, a corporate level tax would be payable
by the consolidated group of which Allergan is the common parent based upon the
difference between the fair market value of our common stock

34



---



##### Table of Contents



Advanced Medical Optics, Inc.

CERTAIN FACTORS AND TRENDS AFFECTING AMO AND ITS BUSINESSES (continued)

and Allergans basis in our common stock distributed to the Allergan
stockholders. Under the consolidated return rules, each member of the
consolidated group (including us) is severally liable for such tax liability.
We have agreed to indemnify Allergan if our actions or the
actions of any of our affiliates result in the tax liability described above.
Allergan has agreed to indemnify us for any losses we may incur in the event
that Allergan or any of its affiliates take any action which adversely impacts
the tax-free nature of the distribution. If we were required to pay any of the
potential taxes described above, the payment would have a material adverse
effect on our financial position.

MANY OF OUR EXECUTIVE OFFICERS AND SOME OF OUR DIRECTORS MAY HAVE POTENTIAL
CONFLICTS OF INTEREST BECAUSE OF THEIR OWNERSHIP OF ALLERGAN COMMON STOCK AND
OTHER TIES TO ALLERGAN.

Many of our executive officers and some of our directors have a portion of
their personal financial portfolios in Allergan common stock or vested options
to purchase Allergan common stock or are employees or former employees of
Allergan. Our directors and executive officers beneficially own less than one
percent of the outstanding Allergan common stock. In addition, we share two
directors with Allergan, including David E.I. Pyott, Allergans Chairman of the
Board, President and Chief Executive Officer. Ownership of Allergan common
stock by our directors and officers or the employment by Allergan of any of our
directors could create, or appear to create, potential conflicts of interest
for these directors and officers when faced with decisions that could have
different implications for Allergan and us.

Risks Relating to Our Industry

WE FACE INTENSE COMPETITION AND OUR FAILURE TO COMPETE EFFECTIVELY COULD HAVE A
MATERIAL ADVERSE EFFECT ON OUR PROFITABILITY AND RESULTS OF OPERATIONS.

The markets for our ophthalmic surgical device and contact lens care products
are intensely competitive and are subject to rapid and significant
technological change. We have numerous competitors in the United States and
abroad, including, among others, large companies such as Alcon, Inc. (a
subsidiary of Nestle S.A.); Bausch & Lomb and its acquired businesses, Chiron
Vision and Storz Ophthalmics; CIBA Vision Corporation; Pharmacia Ophthalmics;
Staar Surgical and Moria. These competitors may develop technologies and
products that are more effective or less costly than any of our current or
future products or that could render our products obsolete or noncompetitive.
Some of these competitors have substantially more resources and a greater
marketing scale than we do. In addition, the
medical technology and device industry continues to experience consolidation,
resulting in an increasing number of companies that are larger and more
diversified than we are. Among other things, these companies can spread their
research and development costs over much broader revenue bases than we can and
can influence customer and distributor buying

35



---



##### Table of Contents



Advanced Medical Optics, Inc.

CERTAIN FACTORS AND TRENDS AFFECTING AMO AND ITS BUSINESSES (continued)

decisions. Our inability to produce and develop products that compete
effectively against our competitors products could result in a material
reduction in sales.

COMPLIANCE WITH THE EXTENSIVE GOVERNMENT REGULATIONS TO WHICH WE ARE SUBJECT IS
EXPENSIVE AND TIME-CONSUMING; AND, IF WE FAIL TO COMPLY WE MAY BE SUBJECT TO
FINES, INJUNCTIONS AND PENALTIES THAT COULD HARM OUR BUSINESS.

Our products and operations are subject to extensive regulation in the United
States by the U.S. Food and Drug Administration. The Food and Drug
Administrations regulations govern, among other things, product development,
product testing, product labeling, manufacturing practices, product storage,
premarket clearance or approval, advertising and promotion, sales and
distribution and postmarket surveillance. Unanticipated changes in existing
regulatory requirements or adoption of new requirements could hurt our
business, financial condition and results of operations.

Numerous regulatory requirements apply to our marketed products, including the
Food and Drug Administrations Quality System Regulations, which require that
our manufacturing operations follow elaborate design, testing, control,
documentation and quality assurance procedures during the manufacturing
process. We are also subject to Food and Drug Administration regulations
covering labeling, adverse event reporting and the Food and Drug
Administrations general prohibition against promoting products for unapproved
or off-label uses. As a medical device manufacturer, our manufacturing
facilities are subject to periodic unannounced inspections to determine
compliance with the extensive regulatory requirements by the Food and Drug
Administration. Although we believe we are in compliance with all applicable
Food and Drug Administration requirements, we cannot be certain that a Food and
Drug Administration inspection would determine that we are in full compliance.
Our failure to comply could lead to warning letters, non-approvals, suspension
of existing approvals, civil penalties and criminal fines, product seizures and
recalls, operating restrictions, injunctions, and criminal prosecutions. The
imposition of any one or more of these penalties could have a material adverse
effect on our production, product sales and profitability.

PRODUCT SALES, INTRODUCTIONS OR MODIFICATIONS MAY BE DELAYED OR CANCELED AS A
RESULT OF THE FOOD AND DRUG ADMINISTRATION REGULATORY PROCESS, WHICH COULD
CAUSE OUR SALES TO DECLINE.

In order for us to market our Class I or Class II (low or medium risk,
respectively) medical devices in the United States, we generally must first
obtain clearance from the U.S. Food and Drug Administration, pursuant to
Section 510(k), or approval pursuant to Section 515, of the Federal Food, Drug,
and Cosmetic Act. Clearance under Section 510(k) requires demonstration that a
new device is substantially equivalent to another legally marketed predicate
device. If we modify our products after they

36



---



##### Table of Contents



Advanced Medical Optics, Inc.

CERTAIN FACTORS AND TRENDS AFFECTING AMO AND ITS BUSINESSES (continued)

receive Food and Drug Administration clearance under Section 510(k), the Food
and Drug Administration may require us to submit a separate 510(k) or premarket
approval application for the modified product before we are permitted to market
the products in the United States. In addition, for our existing or any future
Class III (high risk) devices we are required to obtain Food and Drug
Administration approval by submitting a premarket approval application.
Clearance under Section 515, through submission of a premarket approval
application or PMA, requires demonstration of a reasonable assurance of safety
and effectiveness using valid scientific data. If we modify our Class III
devices or their manufacturing sites or processes following premarket approval,
we may be required to submit a supplemental or new PMA application and obtain
prior approval before marketing the modified products. While the burden of
determining if a modified product requires a new 501(k), PMA supplement or new
PMA is left to us, if the Food and Drug Administration disagrees with our
assessment, it could be deemed a failure to comply and we could become subject
to warning letters, future non-approvals, suspension of existing approvals,
civil penalties and criminal fines, product seizures and recalls, operating
restrictions, injunctions, and criminal prosecutions. The imposition of any one
or more of these penalties could have a material adverse effect on our
production, product sales and profitability.

The Food and Drug Administration may not act favorably or quickly in its review
of our 510(k) or premarket approval application submissions, or we may
encounter significant difficulties and costs in our efforts to obtain Food and
Drug Administration clearance or approval, all of which could delay or preclude
sale of new products in the United States. Furthermore, the Food and Drug
Administration may request additional data, require us to conduct further
testing, or compile more data, including clinical data, in support of a 510(k)
or PMA submission. The Food and Drug Administration may also, instead of
accepting a 510(k) submission, require us to submit a premarket approval
application, which is typically a much more complex application than a 510(k).
To support a premarket approval application, the Food and Drug Administration
would likely require that we conduct one or more clinical studies to
demonstrate that the device is safe and effective, rather than substantially
equivalent to another legally marketed predicate device. We may not be able
to meet the requirements to obtain 510(k) clearance or approval of a premarket
approval application, or the Food and
Drug Administration may not grant any necessary clearances or approvals. In
addition, the Food and Drug Administration may place significant limitations
upon the intended use of our products as a condition to a 510(k) clearance or
approval of a premarket approval application. Product applications can also be
denied or withdrawn due to failure to comply with regulatory requirements or
the occurrence of unforeseen problems following approval. Failure to obtain
Food and Drug Administration clearance or approvals of new products we develop,
any limitations imposed by the Food and Drug Administration on new product use
or the costs of obtaining Food and Drug Administration clearance or approvals
could have a material adverse effect on our business, financial condition and
results of operations.

37



---



##### Table of Contents



Advanced Medical Optics, Inc.

CERTAIN FACTORS AND TRENDS AFFECTING AMO AND ITS BUSINESSES (continued)

In order to conduct a clinical investigation involving human subjects for the
purpose of demonstrating the safety and effectiveness of a device, a company
must, among other things, apply for and obtain Institutional Review Board
approval of the proposed investigation. In addition, if the clinical study
involves a significant risk (as defined by the Food and Drug Administration)
to human health, the sponsor of the investigation must also submit and obtain
Food and Drug Administration approval of an investigational device exemption
application. We may not be able to obtain Food and Drug Administration and/or
Institutional Review Board approval to undertake clinical trials in the U.S.
for any new devices we intend to market in the United States in the future. If
we obtain such approvals, we may not be able to comply with the investigational
device exemption and other regulations governing clinical investigations or the
data from any such trials may not support clearance or approval of the
investigational device. Failure to obtain such approvals or to comply with such
regulations could have a material adverse effect on our business, financial
condition and results of operations.

Additionally, in many of the foreign countries in which we market our products,
we are also subject to regulations applicable to our devices and products that
are similar to those of the Food and Drug Administration. Particular emphasis
is also being placed on more sophisticated and faster procedures for reporting
of adverse events to the competent authorities. In many countries the national
health or social security organizations require our products to be qualified
before they can be marketed with the benefit of reimbursement eligibility.
Failure to receive, or delays in the receipt of, relevant foreign
qualifications also could have a material adverse effect on our business,
financial condition and results of operations. Particular emphasis is also
being placed on more sophisticated and faster procedures for reporting of
adverse events to the competent authorities. In many countries, the national
health or social security organizations require our products to be qualified
before they can be marketed with the benefit of reimbursement eligibility.
Failure to receive, or delays in the receipt of, relevant foreign
qualifications also could have a material adverse effect on our business,
financial condition and results of operations.

The European Union regulatory regime for medical devices became mandatory in
June 1998. It requires that medical devices may only be placed on the market if
they do not compromise safety and health when properly installed, maintained
and used in accordance with their intended purpose. National laws conforming to
this European Union legislation regulate our surgical and contact lens care
products under the medical devices regulatory system, rather than under the
national requirements under which they were formerly regulated, which were
often highly variable. The European Union medical device laws require us to
declare that our products conform to the designated essential requirements,
only after which our products may be placed on the market bearing a CE
marking. The manufacturers quality systems for products in all but the lowest
risk classification are also subject to certification and audit by an
independent notified body.

38



---



##### Table of Contents



Advanced Medical Optics, Inc.

CERTAIN FACTORS AND TRENDS AFFECTING AMO AND ITS BUSINESSES (continued)

In Japan, the regulatory process for our products is also complex.
Pre-marketing approval and clinical studies are required, as is governmental
pricing approval for medical devices. Clinical studies are subject to a
stringent Good Clinical Practices standard. Approval time frames from the
responsible Japanese Ministry vary from simple notifications to review periods
of one or more years, depending on the complexity and risk level of the device.
In addition, importation into Japan of medical devices is subject to Good
Import Practices regulations. As with any highly regulated market, significant
changes in the regulatory environment could adversely affect future sales.

In many of the other foreign countries in which we market our products, we are
subject to regulations affecting, among other things:



| |  |  | product standards;          
| | - |  | ----------------------------
|
| |  |  | packaging requirements;     
|
| |  |  | labeling requirements;      
|
| |  |  | quality system requirements;
|
| |  |  | import restrictions;        
|
| |  |  | tariff regulations;         
|
| |  |  | duties; and                 
|
| |  |  | tax requirements.           

IF WE OR OUR SUBCONTRACTORS FAIL TO COMPLY WITH APPLICABLE MANUFACTURING
REGULATIONS, OUR BUSINESS COULD BE HARMED.

We, our key subcontractors and any third party manufacturers that manufacture
our products that are sold in the United States are required to demonstrate and
maintain compliance with the Food and Drug Administrations Quality System
Regulation. The Quality System Regulation sets forth the Food and Drug
Administrations requirements for good manufacturing practices of medical
devices and includes requirements for, among other things, the manufacturing,
packaging, labeling and distribution of such products. The Food and Drug
Administration enforces the Quality System Regulation through inspections. We
cannot assure you that our key subcontractors or third party manufacturers are
or will continue to be in compliance, or that they will not encounter any
manufacturing difficulties. We also cannot assure you that we, any of our key
subcontractors or any of our third party manufacturers will be able to maintain
compliance with regulatory requirements. The failure of a subcontractor or
third party manufacturer to be compliant with the Quality System Regulation may
disrupt
our ability to supply products sufficient to meet U.S. demand until a new
subcontractor or third party manufacturer has been identified and

39



---



##### Table of Contents



Advanced Medical Optics, Inc.

CERTAIN FACTORS AND TRENDS AFFECTING AMO AND ITS BUSINESSES (continued)

evaluated. Furthermore, we cannot assure you that if we find it necessary to
seek out new subcontractors or third party manufacturers to satisfy our
business requirements, that we will be able to locate new subcontractors or
third party manufacturers who are in compliance with regulatory requirements.
Our failure to do so will have a material adverse effect on our ability to
produce our products and on our profitability.

HEALTH CARE INITIATIVES AND OTHER COST-CONTAINMENT PRESSURES COULD CAUSE US TO
SELL OUR PRODUCTS AT LOWER PRICES, RESULTING IN LESS REVENUE TO US.

Government and private sector initiatives to limit the growth of health care
costs, including price regulation and competitive pricing, are continuing in
many countries where we do business, including the United States and Europe.
As a result of these changes, the marketplace has placed increased emphasis on
the delivery of more cost-effective medical therapies. As a result of the
trend towards managed healthcare in the United States, third party payors are
increasingly limiting both coverage for, and the level of reimbursement of, new
medical procedures and treatments. Various federal and state programs,
including Medicare and Medicaid, provide reimbursement primarily at
predetermined fixed rates. These programs are subject to statutory and
regulatory changes, administrative rulings, interpretations of policy and
governmental funding restrictions, all of which may have the effect of
decreasing program payments, increasing costs or requiring us to modify the way
in which we operate our business. In response to rising Medicare and Medicaid
costs, several legislative proposals in the United States have been advanced
and implemented that restrict payment increases to hospitals and other
providers through reimbursement systems that are based on predetermined payment
rates or other methodologies limiting payment increases. We are
not able to predict whether these changes will take effect or whether other
changes will be made in the rates prescribed by these governmental programs.
For example, reimbursement rates for intraocular lenses by Medicare have
declined in recent years. These governmental rate changes could have a
material and adverse effect on us, including our prospects for future sales of
our products.

In keeping with the increased emphasis on cost effectiveness in health care
delivery, the current trend among hospitals and other customers of medical
device manufacturers is to consolidate into larger purchasing groups to enhance
purchasing power. The medical device industry has also experienced some
consolidation, partly in order to offer a broader range of products to large
purchasers. As a result, transactions with customers are larger, more complex
and tend to involve more long-term contracts than in the past. The enhanced
purchasing power of these larger customers may also increase the pressure on
product pricing, although we are unable to estimate the potential impact at
this time.

These ongoing cost-containment pressures from managed care and hospital buying
groups in the United States and government organizations in Europe and the Asia
Pacific regions have generated over the past decade industry-

40



---



##### Table of Contents



Advanced Medical Optics, Inc.

CERTAIN FACTORS AND TRENDS AFFECTING AMO AND ITS BUSINESSES (continued)

wide net declines in base prices for our ophthalmic surgical products. Base
prices, however, generally have stabilized in more recent years in the United
States and some of these other regions. Although we believe we are
well-positioned to respond to changes resulting from this worldwide trend
toward cost containment, proposed legislation or changes in the marketplace
could have an adverse impact on future operating results.

WE COULD EXPERIENCE LOSSES DUE TO PRODUCT LIABILITY CLAIMS OR PRODUCT RECALLS
OR CORRECTIONS.

We have in the past been, and continue to be, subject to product liability
claims. We have assumed the defense of any litigation involving claims related
to our business and will indemnify Allergan for all related losses, costs and
expenses. As part of our risk management policy, we have obtained third-party
product liability insurance coverage. Product liability claims against us may
exceed the coverage limits of our insurance policies or cause us to record a
self-insured loss. Even if any product liability loss is covered by an
insurance policy, these policies have substantial retentions or deductibles
that provide that we will not receive insurance proceeds until the losses
incurred exceed the amount of those retentions or deductibles. To the extent
that any losses are below these retentions or deductibles, we will be
responsible for paying these losses. A product liability claim in excess of
applicable insurance could have a material adverse effect on our business,
financial position and results of operations.

OUR CONTACT LENS CARE BUSINESS COMPETES IN A MARKET THAT IS GRADUALLY DECLINING
ON A NET GLOBAL BASIS, WHICH COULD MATERIALLY IMPACT OUR OPERATING RESULTS IF
WE CANNOT TIMELY GENERATE NEW SOURCES OF REVENUE.

We believe that revenue growth of the contact lens care market in international
markets is offset by a larger decline in the U.S. market, resulting in a net
global decline of approximately one percent in 2001 as compared to 2000. We
anticipate that this trend will continue or possibly worsen in the near future.
Our contact lens care business is impacted by trends in the contact lens care
market such as technological and medical advances in surgical techniques for
the correction of vision impairment. Less expensive one-bottle chemical
disinfection systems have gained popularity among soft contact lens wearers
instead of peroxide-based lens care products, which historically have been our
strongest family of lens care products. Also, the growing use and acceptance of
daily and extended wear contact lenses and laser correction procedures, along
with the other factors above, could have the effect of continuing to reduce
demand for lens care products generally. We cannot assure you that we have
established appropriate or sufficient marketing and sales plans to mitigate the
effect of these trends upon our contact lens care business. If we cannot
timely
generate new sources of revenue to offset any decline in revenues from these
trends, our operating results will materially suffer.

41



---



##### Table of Contents



Advanced Medical Optics, Inc.

CERTAIN FACTORS AND TRENDS AFFECTING AMO AND ITS BUSINESSES (continued)

Risks Relating to Our Business

IF WE DO NOT INTRODUCE NEW PRODUCTS IN A TIMELY MANNER, OUR PRODUCTS MAY BECOME
OBSOLETE OVER TIME, CUSTOMERS MAY NOT BUY OUR PRODUCTS AND OUR REVENUE AND
PROFITABILITY MAY DECLINE.

Demand for our products may change in ways we may not anticipate because of:



| |  |  | evolving customer needs;                          
| | - |  | --------------------------------------------------
|
| |  |  | the introduction of new products and technologies;
|
| |  |  | evolving surgical practices; and                  
|
| |  |  | evolving industry standards.                      

Without the timely introduction of new products and enhancements, our products
may become obsolete over time, in which case our revenue and operating results
would suffer. The success of our new product offerings will depend on several
factors, including our ability to:



| |  |  | properly identify and anticipate customer needs;                                                                                    
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------
|
| |  |  | commercialize new products in a timely manner;                                                                                      
|
| |  |  | manufacture and deliver products in sufficient volumes on time;                                                                     
|
| |  |  | differentiate our offerings from competitors offerings;                                                                            
|
| |  |  | achieve positive clinical outcomes for new products;                                                                                
|
| |  |  | satisfy the increased demands by healthcare payors, providers and
patients for lower-cost procedures;                               
|
| |  |  | innovate and develop new materials, product designs and surgical
techniques; and                                                    
|
| |  |  | provide adequate medical and/or consumer education relating to new
products and attract key surgeons to advocate these new products.

Moreover, innovations generally will require a substantial investment in
research and development before we can determine the commercial viability of
these innovations and we may not have the financial resources necessary to fund
these innovations. In addition, even if we are able to successfully develop
enhancements or new generations of our products, these enhancements
or new generations of products may not produce revenue in excess of the costs
of development and they may be quickly rendered obsolete by changing customer
preferences or the introduction by our competitors of products embodying new
technologies or features.

42



---



##### Table of Contents



Advanced Medical Optics, Inc.

CERTAIN FACTORS AND TRENDS AFFECTING AMO AND ITS BUSINESSES (continued)

IF WE FAIL TO MAINTAIN OUR RELATIONSHIPS WITH HEALTHCARE PROVIDERS, CUSTOMERS
MAY NOT BUY OUR PRODUCTS AND OUR REVENUE AND PROFITABILITY MAY DECLINE.

We market our products to numerous health care providers, including eye care
professionals, hospitals, ambulatory surgical centers, corporate optometry
chains and group purchasing organizations. We have developed and strive to
maintain close relationships with members of each of these groups who, at
times, assist in product research and development and advise us on how to
satisfy the full range of surgeon and patient needs. We rely on these groups to
recommend our products to their patients and to other members of their
organizations. The failure of our existing products and any new products we may
introduce to retain the support of these various groups could have a material
adverse effect on our business, financial condition and results of operations.

WE CONDUCT A SIGNIFICANT AMOUNT OF OUR SALES AND OPERATIONS OUTSIDE OF THE
UNITED STATES, WHICH SUBJECTS US TO ADDITIONAL BUSINESS RISKS, SUCH AS BUSINESS
INTERRUPTION AND INCREASED COSTS, AND MAY CAUSE OUR PROFITABILITY TO DECLINE.

Because we manufacture and sell our products in a number of foreign countries,
our business is subject to risks associated with doing business
internationally. In particular, our two manufacturing sites are located
outside the continental United States, in Anasco, Puerto Rico and Hangzhou,
China, and in 2001, we derived approximately $376 million, or 69% of our total
revenue, from sales of our products outside of the United States. In addition,
in 2001 we derived approximately 25.3% of our net sales in Japan. We intend to
continue to pursue growth opportunities in sales internationally, which could
expose us to greater risks associated with international sales and operations.
Our international operations are, and will continue to be, subject to a number
of risks and potential costs, including:



| |  |  | unexpected changes in foreign regulatory requirements;                                        
| | - |  | ----------------------------------------------------------------------------------------------
|
| |  |  | differing local product preferences and product requirements;                                 
|
| |  |  | fluctuations in foreign currency exchange rates;                                              
|
| |  |  | political and economic instability;                                                           
|
| |  |  | changes in foreign medical reimbursement and coverage policies and
programs;                  
|
| |  |  | diminished protection of intellectual property in some countries
outside of the United States;
|
| |  |  | trade protection measures and import or export licensing requirements;                        

43



---



##### Table of Contents



Advanced Medical Optics, Inc.

CERTAIN FACTORS AND TRENDS AFFECTING AMO AND ITS BUSINESSES (continued)



| |  |  | difficulty in staffing and managing foreign operations;    
| | - |  | -----------------------------------------------------------
|
| |  |  | differing labor regulations; and                           
|
| |  |  | potentially negative consequences from changes in tax laws.

Any of these factors may, individually or as a group, have a material adverse
effect on our business and results of operations. In addition, we are
particularly susceptible to the occurrence of any of these risks in Japan due
to our high concentration of sales in Japan.

As we expand our international operations, we may encounter new risks. For
example, as we focus on building our international sales and distribution
networks in new geographic regions, we must continue to develop relationships
with qualified local distributors and trading companies. If we are not
successful in developing these relationships, we may not be able to grow sales
in these geographic regions. These or other similar risks could adversely
affect our revenue and profitability.

WE ARE SUBJECT TO RISKS ARISING FROM CURRENCY EXCHANGE RATE FLUCTUATIONS, WHICH
COULD INCREASE OUR COSTS AND MAY CAUSE OUR PROFITABILITY TO DECLINE.

Since a significant portion of our international sales and manufacturing costs
are denominated in local currencies and not in U.S. dollars, our reported sales
and earnings are subject to fluctuations in foreign exchange rates. Significant
increases in the value of the United States dollar relative to foreign
currencies, including the Japanese Yen or the Euro, could have a material
adverse effect on our results of operations. Currency risk management for our
business has historically been managed by Allergans treasury operations. As
part of this strategy, Allergan has used financial instruments to reduce its
exposure to adverse movements in currency exchange rates. As an independent
company, we have implemented a hedging policy that attempts to manage currency
exchange rate risks to an acceptable level based on managements judgment of
the appropriate trade-off between risk, opportunity and cost; however, this
hedging policy may not successfully eliminate the effects of currency exchange
rate fluctuations.

IF WE ARE UNABLE TO PROTECT OUR INTELLECTUAL PROPERTY RIGHTS, OUR BUSINESS AND
PROSPECTS MAY BE HARMED.

Our ability to compete effectively is dependent upon the proprietary nature of
the designs, processes, technologies and materials owned, used by or licensed
to us. Although we attempt to protect our proprietary property,
technologies and processes through a combination of patent law, trade secrets
and non-disclosure agreements, these may be insufficient. For example, in the
case of patents, it is possible that existing patents granted to us or our
licensors will be invalidated. Patents currently or prospectively applied for
by us or our licensors may not be granted. Even if patents are granted, this
does not assure that they will provide

44



---



##### Table of Contents



Advanced Medical Optics, Inc.

CERTAIN FACTORS AND TRENDS AFFECTING AMO AND ITS BUSINESSES (continued)

significant commercial benefits. Moreover, it is possible that competing
companies may circumvent our patents or our licensors patents by developing
products that closely emulate but do not infringe these patents.

This would allow our competitors to market products that compete with our
products without obtaining a license from us. In addition to patented or
potentially patentable designs, technologies, processes and materials, we also
rely on proprietary designs, technologies, processes and procedures to protect
against improper disclosure of these trade secrets. It is possible, however,
that competitors could independently develop the same or superior designs,
technologies, processes and know-how. It is also possible that our trade
secrets could be improperly disclosed in spite of our protective procedures.

We believe that the international market for our products is as important as
the domestic market, and therefore we seek patent protection for our products
or those of our licensors in foreign countries where we feel such protection is
needed. Because of the differences in foreign patent and
other laws concerning proprietary rights, our products may not receive the same
degree of protection in foreign countries as they would in the United States.

WE MAY BE SUBJECT TO INTELLECTUAL PROPERTY LITIGATION AND INFRINGEMENT CLAIMS,
WHICH COULD CAUSE US TO INCUR SIGNIFICANT EXPENSES OR PREVENT US FROM SELLING
OUR PRODUCTS.

There is a substantial amount of litigation over patent and other intellectual
property rights in the eye care industry, and in the ophthalmic surgical device
and contact lens care markets particularly. The fact that we have patents
issued to us for our products does not mean that we will always be able to
successfully defend our patents and proprietary rights against challenges or
claims of infringement by our competitors. A successful claim of patent or
other intellectual property infringement against us could adversely affect our
growth and profitability, in some cases materially. We cannot assure you that
others will not claim that our proprietary or licensed products are infringing
their intellectual property rights or that we do not in fact infringe those
intellectual property rights. From time to time, we receive notices from third
parties of potential infringement and receive claims of potential infringement.
We may be unaware of intellectual property rights of others that may cover some
of our technology. If someone claims that our products infringed their
intellectual property rights, any resulting litigation could be costly and time
consuming and would divert the attention of management and key
personnel from other business issues. The complexity of the technology involved
and the uncertainty of intellectual property litigation increase these risks.
Claims of intellectual property infringement also might require us to enter
into costly royalty or license agreements. However, we may be unable to obtain
royalty or license agreements on terms acceptable to us or at all. We also may
be subject to significant damages or an injunction preventing us from
manufacturing, selling or using some of our

45



---



##### Table of Contents



Advanced Medical Optics, Inc.

CERTAIN FACTORS AND TRENDS AFFECTING AMO AND ITS BUSINESSES (continued)

products in the event of a successful claim of patent or other intellectual
property infringement. Any of these adverse consequences could have a material
adverse effect on our business and profitability.

IF WE EXPERIENCE AN INTERRUPTION OF OUR MANUFACTURING OPERATIONS, OUR BUSINESS,
FINANCIAL CONDITION AND OPERATING RESULTS WOULD BE MATERIALLY HARMED.

We rely on third parties to manufacture a significant portion of our products,
and we manufacture the remainder. As a result, any prolonged disruption in the
operation of our manufacturing facilities or those of our third party
manufacturers, whether due to technical, labor or other difficulties,
destruction of or damage to any facility or other reasons, could materially
harm our business, financial condition and operating results.

OUR MANUFACTURING CAPACITY MAY NOT BE ADEQUATE TO MEET THE DEMANDS ON OUR
BUSINESS.

We manufacture our products or contract with third parties to manufacture our
products. Our products are manufactured in quantities sufficient to satisfy our
current level of product sales. If we experience increases in sales, we will
need to increase our production significantly beyond our present manufacturing
capacity. Additionally, in June 2005 our manufacturing agreement with Allergan
will terminate and we will be required to increase our manufacturing capacities
or to contract with additional parties to manufacture our products. The process
to transfer manufacturing of our products to new facilities is lengthy and
requires regulatory approval. We cannot assure you that we can successfully
increase our capacity on a profitable basis, complete the regulatory approval
process in a timely manner, or contract with additional parties on terms
acceptance to us, if at all. Any prolonged disruption in the operation of our
manufacturing facilities or those of our third party manufacturers could
materially harm our business. Furthermore, we cannot assure you that if we
choose to scale-up our manufacturing operations, we will be able to maintain
compliance with Food and Drug Administration or other regulatory standards.

IF WE FAIL TO RETAIN THE INDEPENDENT AGENTS AND DISTRIBUTORS UPON WHOM WE RELY
HEAVILY TO MARKET OUR PRODUCTS, CUSTOMERS MAY NOT BUY OUR PRODUCTS AND OUR
REVENUE AND PROFITABILITY MAY DECLINE.

Our marketing success in the United States and abroad depends largely upon our
agents and distributors sales and service expertise and relationships with
the customers in the marketplace. Many of these agents have developed strong
ties to existing and potential customers because of their detailed knowledge of
products and instruments and commonly provide operating room personnel with
implant and instrument product training as well as product support in the
operating room. A significant loss of these agents could have a material
adverse effect on our business. As part of the

46



---



##### Table of Contents



Advanced Medical Optics, Inc.

CERTAIN FACTORS AND TRENDS AFFECTING AMO AND ITS BUSINESSES (continued)

reorganization of Allergan resulting in our formation, we will need to obtain
new distributors in several markets in which we are unable to deploy our own
sales force. Any new distributors we obtain will likely be unfamiliar with our
products. We cannot assure you that we will be able to obtain new distributors
in a timely manner or on terms that are acceptable to us. Our inability to find
new distributors in a timely manner and the unfamiliarity of any new
distributors with our products could result in lost sales in these countries.

IF WE FAIL TO ATTRACT, HIRE AND RETAIN QUALIFIED PERSONNEL, WE MAY NOT BE ABLE
TO DESIGN, DEVELOP, MARKET OR SELL OUR PRODUCTS OR SUCCESSFULLY MANAGE OUR
BUSINESS.

Our ability to attract new customers, retain existing customers and pursue our
strategic objectives depends on the continued services of our current
management, sales, product development and technical personnel and our ability
to identify, attract, train and retain similar personnel.

Competition for top management personnel is intense and we may not be able to
recruit and retain the personnel we need. The loss of any one of our management
personnel, or our inability to identify, attract, retain and integrate
additional qualified management personnel, could make it difficult for us to
manage our business successfully and pursue our strategic objectives.

Similarly, competition for skilled sales, product development and technical
personnel is intense and we may not be able to recruit and retain the personnel
we need. The loss of the services of any key sales, product development and
technical personnel, or our inability to hire new personnel with the requisite
skills, could restrict our ability to develop new products or enhance existing
products in a timely manner, sell products to our customers or manage our
business effectively.

We may not be able to hire or retain qualified personnel if we are unable to
offer competitive salaries and benefits, or if our stock does not perform well.
In addition, as an independent company, separate from Allergan, we may find it
more difficult to attract personnel. We may have
to increase our salaries and benefits, which would increase our expenses and
reduce our profitability.

Risks Related to Ownership of Our Common Stock

47



---



##### Table of Contents



Advanced Medical Optics, Inc.

CERTAIN FACTORS AND TRENDS AFFECTING AMO AND ITS BUSINESSES (continued)

BECAUSE OUR QUARTERLY REVENUE AND OPERATING RESULTS MAY VARY SIGNIFICANTLY IN
FUTURE PERIODS, OUR STOCK PRICE MAY DECLINE.

Our revenue and operating results may vary significantly from quarter to
quarter. A high proportion of our costs are fixed, due in part to significant
selling, research and development and manufacturing costs. Thus, small declines
in revenue could disproportionately affect operating results in a quarter and
the price of our common stock may fall. Other factors that could affect
quarterly operating results include:



| |  |  | the timing and execution of customer contracts;                                                                              
| | - |  | -----------------------------------------------------------------------------------------------------------------------------
|
| |  |  | the timing of sales of products;                                                                                             
|
| |  |  | changes in foreign currency exchange rates;                                                                                  
|
| |  |  | unanticipated delays or problems in introducing new products;                                                                
|
| |  |  | competitors announcements of new products, services or technological
innovations;                                           
|
| |  |  | changes in our pricing policies or the pricing policies of our
competitors;                                                  
|
| |  |  | the failure of third-party payors to reimburse our surgeons and
patients or changes in reimbursement levels;                 
|
| |  |  | increased expenses, whether related to sales and marketing, raw
materials or supplies, product development or administration;
|
| |  |  | adverse changes in the level of economic activity in the United
States and other major regions in which we do business;      

48



---



##### Table of Contents



Advanced Medical Optics, Inc.

CERTAIN FACTORS AND TRENDS AFFECTING AMO AND ITS BUSINESSES (continued)



| |  |  | costs related to possible acquisitions of technologies or businesses;        
| | - |  | -----------------------------------------------------------------------------
|
| |  |  | an increase in the number or magnitude of product liability claims;          
|
| |  |  | changes in our effective income tax rate;                                    
|
| |  |  | our ability to expand our operations; and                                    
|
| |  |  | the amount and timing of expenditures related to expansion of our
operations.

THE TERMS OF OUR SEPARATION FROM ALLERGAN, ANTI-TAKEOVER PROVISIONS OF OUR
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION AND AMENDED AND RESTATED
BYLAWS, OUR RIGHTS AGREEMENT AND PROVISION OF DELAWARE LAW COULD DELAY OR
PREVENT A CHANGE OF CONTROL THAT YOU MAY FAVOR.

The term of our separation from Allergan could delay or prevent a change of
control that our stockholders may favor. Any acquisitions of our stock or any
issuances of our stock that represent 50% or more of our stock in the
aggregate, and, in each case, that related to the distribution, would cause the
distribution to be a taxable transaction to Allergan. Under the tax sharing
agreement we would be required to indemnify Allergan for the resulting tax, and
we would be required to meet various requirements, including obtaining the
approval of Allergan before engaging in specified transactions relating to the
distribution that involve the acquisition of our stock or the issuance of our
stock. These obligations might discourage, delay or prevent a change of
control that our stockholders may considerable favorable.

49



---



##### Table of Contents



Advanced Medical Optics, Inc.

CERTAIN FACTORS AND TRENDS AFFECTING AMO AND ITS BUSINESSES (continued)

Provisions of our amended and restated certificate of incorporation, amended
and restated bylaws and our rights agreement also may discourage, delay or
prevent a merger or other change of control that our stockholders may consider
favorable or may impede the ability of the holders of our common stock to
change our management. The provisions of our amended and
restated certificate of incorporation and amended and restated by bylaws, among
other things:



| |  |  | authorize our board of directors to establish one or more series of
undesignated preferred stock, the terms of which can be determined by
the board of directors at a time of issuance;                                                                                                                                                                                                                                                                                                                                                                                 
| | - |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|
| |  |  | divide our board of directors into three classes of directors, with
each class serving a staggered three-year term. Because the
classification of the board of directors generally increases the
difficulty of replacing a majority of the directors, it may tend to
discourage a third party from making a tender offer or otherwise
attempting to obtain control of us and may make it difficult to change
the composition of the board of directors;                                                                                                                 
|
| |  |  | provide that directors may be removed by stockholders only for cause;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
|
| |  |  | not provide for cumulative voting in the election of directors which,
if allowed, could enable a minority stockholder holding a sufficient
percentage of a class of shares to ensure the election of one or more
directors;                                                                                                                                                                                                                                                                                                                                             
|
| |  |  | require that any action required or permitted to be taken by our
stockholders must be effected at a duly called annual or special meeting
of stockholders and may not be effected by any consent in writing;                                                                                                                                                                                                                                                                                                                                                            
|
| |  |  | state that special meetings of our stockholders may be called only by
our board of directors, the chairman of the board of directors, or our
president;                                                                                                                                                                                                                                                                                                                                                                                                                 
|
| |  |  | establish advance notice requirements for submitting nominations for
election to the board of directors and for proposing matters that can be
acted upon by stockholders at a meeting;                                                                                                                                                                                                                                                                                                                                                                                  
|
| |  |  | provide that specified transactions benefiting a holder of greater
than 15% of our outstanding common stock, an interested stockholder,
must comply with procedures designed to ensure that our stockholders
receive a fair price and are otherwise adequately informed of the
transaction or be approved by either (i) the holders of a supermajority
of our outstanding common stock and the holders of a majority of our
outstanding common stock that is not held by the interested stockholder
or its affiliates or (ii) a majority of the disinterested directors;
|
| |  |  | provide that certain provisions of our amended and restated
certificate of incorporation can be amended only by supermajority vote
of the outstanding shares, and that our bylaws can be amended only by                                                                                                                                                                                                                                                                                                                                                                

50



---



##### Table of Contents



Advanced Medical Optics, Inc.

CERTAIN FACTORS AND TRENDS AFFECTING AMO AND ITS BUSINESSES (continued)



| |   |  | supermajority vote of the outstanding shares or by our board of directors;                                  
| | - |  | ------------------------------------------------------------------------------------------------------------
|
| |  |  | allow only incumbent directors, not our stockholders, to fill
vacancies on our board of directors; and      
|
| |  |  | provide that the authorized number of directors may be changed only
by resolution of the board of directors.

In addition, because we are subject to Section 203 of the Delaware General
Corporation Law, this provision could also delay or prevent a change of control
that you may favor. Section 203 provides that, subject to limited exceptions,
any person that acquires, or is affiliated with a person that acquires, more
than 15% of the outstanding voting stock of a Delaware corporation shall not
engage in any business combination with that corporation, including by merger,
consolidation or acquisitions of additional shares, for a three-year period
following the date on which that person or its affiliate becomes a 15%
stockholder.

51



---



##### Table of Contents



Advanced Medical Optics, Inc.




ADVANCED MEDICAL OPTICS, INC.

PART II  OTHER INFORMATION




Item 4. Submission of Matters to a Vote of Security Holders

On June 19, 2002 in actions by written consent, Allergan, as our sole
stockholder prior to our spin-off on June 29, 2002, approved our stock-based
employee benefit plans, including:



| |  |  | Advanced Medical Optics, Inc. 2002 Incentive Compensation Plan;      
| | - |  | ---------------------------------------------------------------------
|
| |  |  | Advanced Medical Optics, Inc. 2002 Employee Stock Purchase Plan;     
|
| |  |  | Advanced Medical Optics, Inc. 2002 International Stock Purchase
Plan;
|
| |  |  | AMO (Ireland) Share Participation
Scheme; and                        
|
| |  |  | AMO Irish Savings Related Share
Option Scheme.                       

On May 1, 2002 in an action by written consent, Allergan, as our sole
stockholder, approved our amended and restated certificate of incorporation and
amended and restated bylaws and confirmed our board of directors, as then
comprised.




Item 5. Other Information

AMO has set April 30, 2003 as the date for its first annual meeting of
stockholders. Any AMO stockholder wishing to have a proposal considered for
inclusion in the AMO 2003 proxy solicitation materials must, in addition to
other applicable requirements, set forth the proposal in writing and send the
proposal to the Secretary of AMO so that it is received between December 31,
2002 and January 30, 2003.

AMOs Chief Executive Officer and Chief Financial Officer have each signed the
certifications required by Section 906 of the Sarbanes-Oxley Act of 2002, which
certifications accompany this filing in the form of correspondence to the
Securities and Exchange Commission. In conjunction with our spin-off from
Allergan, Allergan has been responsible for our historical combined financial
statements for all periods up to and including this quarter. AMOs Chief
Executive Officer and Chief Financial Officer have relied on the information
provided from Allergan in making these certifications.




Item 6. Exhibits and Reports on Form 8-K



| |  |  | Exhibits
 
  - None
| | - |  | -------------------
|
| |  |  | Reports on Form 8-k

| |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
| | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| | On June 18, 2002, the Company filed a Current Report on Form 8-k
announcing that the Company had entered into a purchase agreement with
respect to the offer and sale of its $200,000,000 in aggregate principal
amount of 9-1/4% Senior Subordinated Notes due 2010 in a private
placement. The report also included the Unaudited Pro Forma Combined
Statements of Earnings for the year ended December 31, 2001, the three
months ended March 30, 2001, the three and the twelve
months ended March 29, 2002, as well as the Unaudited Pro Forma Combined
Balance Sheet as of March 29, 2002.

52



---



##### Table of Contents



ADVANCED MEDICAL OPTICS, INC.

PART II  OTHER INFORMATION (continued)

| |                                                                                                                                                                                                                                                                             
| | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| | On June 25, 2002, the Company filed a Current Report on Form 8-k
announcing the Companys adoption of a Stockholder Rights Plan, the
expansion of the Companys Board of Directors to seven members, and a
form of manufacturing agreement to be entered into with Allergan.

53



---



##### Table of Contents






SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

|      |  |                 |  |                                                   
|----- |  | --------------- |  | --------------------------------------------------
|Date: |  | August 12, 2002 |  | ADVANCED MEDICAL OPTICS, INC.                     
|      |  |                 |  |                                                   
|      |  |                 |  | /s/   Robert F. Gallagher                         
|      |  |                 |  |                                                   
|      |  |                 |  | Robert F. Gallagher
(Principal Accounting Officer)

54